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ABSTRACT OF DISSERTATION 
 
 
THERMODYNAMICS AND KINETICS OF THE THREE-WAY JUNCTION OF 
PHI29 MOTOR PRNA AND ITS ASSEMBLY INTO NANOPARTICLES FOR 
THERAPEUTIC DELIVERY TO PROSTATE CANCER 
 
The emerging field of RNA nanotechnology necessitates creation of functional 
RNA nanoparticles, but has been limited by particle instability. Previously, it was found 
the three-way junction (3WJ) of the Phi29 DNA packaging motor pRNA was found to be 
ultra-stable and assemble in solution without the presence of metal ions. The three-way 
junction is composed of three short oligo RNA strands and proven to be thermodynamically 
stable. Here the assembly mechanism, thermodynamic and enzymatic stabilities, and 
kinetics are examined in order to understand the stability behind this unique motif. 
Thermodynamic and kinetics studies found that the pRNA 3WJ formed out of three 
components at a rapid rate creating a single-step three component collision with a lack of 
dimer intermediate formation while being governed by entropy, instead of the commonly 
seen enthalpy. Furthermore, the pRNA 3WJ proved to be stable at temperatures above 50 
°C, concentrations below 100 pM, and produced a free energy of formation well below 
other studied RNA structures and motifs. With the high stability and folding efficiency of 
the pRNA 3WJ, it serves as an ideal platform for multi-branched RNA nanoparticles 
constructed through bottom-up techniques. RNA nanoparticles were constructed for the 
specific targeting of prostate cancer cells expressing Prostate Specific Membrane Antigen 
(PSMA) by receptor mediated endocytosis through the addition of an RNA aptamer; and 
the delivery of anti-miRNA sequences for gene regulation. The resulting nanoparticles 
remained stable while showing highly specific binding and entry in PSMA positive cells 
through cell surface receptor endocytosis. Furthermore, the entry of the nanoparticles 
allowed for the knockdown of against onco-miRNAs. Nanoparticles harboring anti-
miRNAs led to the upregulation of tumor suppressor genes, and signaling of apoptotic 
pathways. These findings display RNA nanotechnology can result in the production of 
stable nanoparticles and result in the specific treatment of cancers, specifically prostate 
cancer. 
 
KEYWORDS: RNA Nanotechnology, Phi29 Packaging Motor, Thermodynamics, 
Kinetics, Prostate Cancer 
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Chapter 1: Introduction and Literature Review 
BRIEF SUMMARY: 
 Chapter 1 begins this thesis with an overview on the creation and necessitation of 
RNA nanotechnology. First the promise of RNA interference technology is examined, 
and how RNA nanotechnology improves the delivery of RNA therapeutics for the 
treatment of cancers and viral diseases. Next the importance of particles stability is 
looked at by examining thermodynamic and kinetic properties. Finally, these parameters 
are discussed in the design of RNA nanoparticles. 
 Chapter 2 looks at the thermodynamic stability of the pRNA-3WJ. Here the 
stability of the RNA motif is compared to its DNA and chemically modified 2’-Fluoro 
RNA species in effort to stabilize the motif against nucleases and improve the 
thermodynamic stability and parameters. It was found the 2’-Fluoro RNA not only 
provides nuclease resistance, but also enhance the thermodynamic properties by 
increasing the melting temperature and decreasing the change in Gibbs free energy. 
Through these tests, it was found that the pRNA-3WJ forms through a rapid association 
in which no dimer intermediate could be detected and the formation of the RNA species 
assemble by an increased change in entropy over the DNA species, compared to the 
commonly seen more favorable change in enthalpy and decrease in entropy. 
 Chapter 3 studies the assembly mechanism of the pRNA-3WJ is examined more 
in-depth. Primarily using surface plasmon resonance, kinetic parameters of the pRNA-
3WJ are elucidated resulting in the discovering the assembly mechanism of the pRNA-
3WJ. It was found the 3WJ formed through a two-step association, forming an 
intermediate that then instantly resulted in the recruitment of the third RNA strand, thus 
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creating the pRNA-3WJ at an unobservable rate. Additionally, it was discovered the 
pRNA-3WJ relied on each of its helical regions for either the rapid formation or the long 
lasting stability. This rapid and unique assembly mechanism proves the pRNA-3WJ 
reactants forms into the 3WJ with a high efficiency and yield that can be translated to the 
production of RNA nanoparticles. 
 Chapter 4 takes the findings from the second and third chapters and applies them 
to the production of RNA nanoparticles for the targeting and treatment of prostate cancer. 
Stable RNA nanoparticles were constructed using the pRNA-3WJ as the central core with 
an RNA aptamer to target Prostate Specific Membrane Antigen (PSMA) and anti-miRNA 
sequences for therapeutic treatment. It was found that the resulting RNA nanoparticles 
were able to specifically bind and enter PSMA expressing cancer cells, delivering the 
anti-miRNA sequences. This specific delivery led to knockdown of the miRNAs, thus 
upregulating tumor suppressor genes and sensitizing cells to apoptosis. These findings 
demonstrates the versatility and ability of the pRNA-3WJ as RNA nanoparticles that has 
previously been unobtainable. 
 Chapter 5 briefly summarizes the major findings and advancements of RNA 
nanotechnology discussed in this thesis dissertation. Furthermore, the future direction of 
this work is described providing a prospective on research that is still needed to fully 
prove the benefits of RNA nanotechnology. Finally, the current state of RNA 
nanotechnology is discussed looking at the major hurdles that have been solved and look 
at how the recent advancements can propel RNA nanotechnology into the cancer 
therapeutic spotlight. 
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HYPOTHESIS: 
 The 3WJ motif from Phi29 bacteriophage packaging RNA (pRNA) provides a 
stable RNA scaffold for the construction of nanoparticles for the treatment of cancers. 
 
INTRODUCTION: 
Nanotechnology and drug delivery 
 First realized by Richard Feynman in 1959, the field of nanotechnology is the 
control of materials in design, interactions, and function at the atomic and molecular level 
(1). It wasn’t until the 1980s when the principles of nanotechnology were put into 
practice by K. Eric Drexler; when he proposed the building of nanomachines capable of 
self-replication (2). Nanotechnology was later defined by the National Nanotechnology 
Initiative to be the manipulation of materials with the size range of 1 – 100 nm in size. As 
technologies advanced through the years, the field of nanotechnology grew as scientists 
were able to image and analyze the particles using techniques such as atomic force 
microscopy (AFM), transmission electron microscopy (TEM), and scanning tunnel 
microscopy (STM). Nanoparticles have since been created from a wide array of materials 
such as lipids (3); polymers (4); proteins and peptides (5); viruses and viral components 
(6); carbons (7); heavy metals, such as gold (8) and silver (9); iron oxide (10); 
deoxyribonucleic acid (DNA) (11); and ribonucleic acid (RNA) (12). 
 While the field of RNA nanotechnology has spread to a vast array of applications, 
a currently developing and promising application is drug delivery (13,14). The principle 
of nanotechnology in drug delivery is to increase the bioavailability of drugs or 
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therapeutic agents (15,16). As numerous drugs currently being developed have solubility 
(17) or toxicity issues, their practical application for the treatment of diseases are truly 
limited. Nanoparticles have been proven to link, uptake and attach to said drugs in hopes 
of increasing delivery to targeted diseases (18-23). Nanoparticle formulations have been 
shown to increase the solubility of difficult drugs; deliver a high dosage of therapeutics at 
desired sites through drug release mechanisms, such as pH sensitive binding and release 
particles (24-28); and provide specific targeting to cells through the use of peptide (29-
31) and aptamer ligands, RNA motifs that have been specially designed and selected for 
binding to chemical and protein substrates such as cell surface receptors (32,33). As a 
result, toxicity is decreased as a smaller total drug concentration is delivered in vivo, all 
while a higher local dosage is delivered to targeted sites.  
While each nanoparticle material provides its own set of advantages and 
disadvantages; as a whole nanotechnology is still a developing field that is still working 
on overcoming hurdles to produce a more perfect drug delivery vehicle and improve on 
current standards of pharmaceutics. Lipid based nanoparticles allow for high drug or 
therapeutic loading and encapsulation and allow for high delivery of payloads through 
membrane fusion with cells while remaining nontoxic and not producing immune 
responses (34,35); however, such nanoparticles have shown issues with thermodynamic 
stability causing release of payload prematurely (36) and issues with production 
reproducibility resulting in the production of inconsistent products (37). Similarly 
polymer based nanoparticles allow for high levels of therapeutic encapsulation (38); 
however, polymers display a significant increase in thermodynamic stability and can 
easily be functionalized on the surface for targeting abilities (39). Yet polymers still show 
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issues with batch reproducibility and have shown issues with solubility and 
bioavailability. Biologically derived nanoparticles such as viruses, viral components and 
proteins and peptides have issues of producing immune responses and creating certain 
levels of toxicity. Yet targeted delivery allows for a lower overall dose while having a 
high accumulation in targeted tissues (40-43). Inorganic nanoparticles such as carbon 
structures and metal ions can be created with high reproducibility with a lower cost than 
most nanoparticles. Furthermore, these particles can be functionalized through chemical 
modifications; however, their high accumulation in healthy organs such as kidneys, 
lungs, and liver result in high toxicity and limit their overall ability for therapeutic 
delivery. DNA nanostructures are constructed with defined shape, size, and stoichiometry 
(44-46) and can achieve targeted delivery with the functionalization of DNA aptamers 
(47,48); yet the overall low thermodynamic stability of DNA nanoparticles limits their 
ability for in vivo applications. Additionally, positively charged nanoparticles such as 
metal ions, some polymers, proteins have overall positive charges that allows for 
endosomal escape through proton sponge effect (49), yet this positive charge allows for 
passive binding to negatively charge cells membranes, leading to non-specific binding to 
healthy tissues producing toxicities. 
The promises of RNA interference in therapeutics 
 The discovery of RNA interference (RNAi), in which RNA sequences create gene 
regulation by the binding and degradation of messenger RNA, by Craig Mello and 
Andrew Fire in 1998 lead to revolutionary work in the RNA field (50). Their discovery of 
RNAs in C. elegans proved that RNA was not simply a temporary intermediate of the 
production of proteins from DNA through transcription and translation, but that RNA 
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plays and essential role in cell functioning and processing. Additionally the discovery of 
functional RNA, dismissed the myth of “junk DNA and RNA.” Their work discovered 
microRNA (miRNA), a naturally occurring RNA loop on messenger RNA (mRNA) that 
is processed into single stranded RNA that is then able to bind and silence several 
mRNAs resulting in gene regulation. Since Mello and Fire’s original work, studies of 
miRNA and its role in gene regulation, cell functionality, and role in disease development 
has exploded into a large field of study. Additionally the development of small interfering 
RNA (siRNA) by David Baulcombe (51) in plants and in mammalian cells by Thomas 
Tuschl (52,53) provided a novel method of gene regulation and proposed method of 
controlling cell growth, gene regulation, and even apoptosis (54-57). Much like miRNA, 
siRNA silences mRNAs and genes however, the sequences are synthetic and designed for 
a single gene while miRNA targets several genes. 
 The discovery of RNAi has heightened interests in using the short RNA 
sequences for RNA therapeutics (50). Many efforts have been made in delivery RNAi 
therapeutics for the treatment of diseases, most notably in cancers and viral infections 
(54-62). However, trials of testing the delivery of naked siRNA led to disappointing 
results, as the short RNA sequences were either quickly degraded by commonly 
occurring RNases or displayed short half-lives of only 15-45 minutes by being excreted 
through the liver due to their small size (63-65). Nanotechnology has since gained a large 
interest in the delivery of RNAi therapeutics in various disease states due to the principles 
of nanoparticles increasing the size of the siRNA or miRNA and protecting the RNA 
strands from nuclease degradation (54-62). Furthermore nanoparticles have proven 
beneficial in delivering payloads to cancer tumors due to their ability to pass through 
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leaky blood vasculature creating the enhanced permeability and retention (EPR) effect, 
while remaining large enough to stay in circulation in the body (66-70). 
 Recently, a new attractive RNAi therapeutic has been developed for the treatment 
of cancers. miRNAs have been shown to play a large role in cancer development whether 
they are either overexpressed or reduced in expression (71-77). Modified locked nucleic 
acid (LNA) sequences have been selected and developed to bind to miRNA seed-regions 
(78), resulting in the inactivation and silencing of microRNAs. This can serve as 
potentially powerful therapeutic to target over expressed miRNA with cancers known as 
oncomirs. While these anti-miRNA LNAs are too small to be delivered directly, as they 
would be immediately be cleared from the body, efforts have been made in delivering 
such LNAs through the incorporation onto nanoparticles. Several technologies have 
encapsulated an anti-miRNA 21 strand into polymer based nanoparticles for the delivery 
to triple negative breast cancer (79), lipid nanoparticles to glioblastroma (80) and lung 
cancer (81), and a lipid-gold nanoparticle hybrid delivered to androgen independent 
prostate cancer (82). Additionally anti-miR21 has been placed onto RNA nanoparticles 
for the specific delivery and treatment of breast cancers (83). Additionally polymer 
nanoparticles have been used to deliver an anti-miRNA 10b sequence to breast cancer 
(79) and metal nanoparticles also delivered anti-miR10b to breast cancers (84). Cheng et. 
al.  used a pH sensitive peptide nanoparticle system for the specific delivery of anti-
miR155 to lymphoma without the accumulation of nanoparticles in healthy tissue (85). 
The wide array of research being completed on several cancer lines and several oncomirs 
indicated the power of the anti-miRNA LNAs and the current interest in the RNAi field. 
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Birth of RNA nanotechnology 
 The concept of RNA was first proven in 1998 (12) through the creation of a 
hexameric ring of packaging RNA (pRNA) on the Phi29 bacteriophage for the packaging 
of viral DNA into the procapsid of virus during replication. The discovery and 
development of inter-molecular interactions between pRNAs, deemed loop-loop 
interactions, proved specific control the looped sequences forming the inter-RNA 
interactions. These interactions allowed for the assembly of the pRNA ring and the 
number of pRNA copies in the ring could therefore be controlled. pRNA is a ~120 base 
pair (bp) RNA structure that serves as a binding sight between the Phi29 connector pore 
that allows for the packaging of the genome into the virus procapsid and the gp16 
ATPase. RNA is an ideal platform for the creation of nanoparticles due to its beneficial 
characteristics listed below. RNA is primarily composed of four nucleotides, adenine(A), 
cytosine (C), guanine (G) and uracil (U); giving RNA the simplistic design of DNA. This 
concept allows for the construction of molecules with easily predictable structures with 
defined shapes and stoichiometry (12,86-88). However, unlike DNA, ribonucleic acids 
allow for non-canonical base pairing, or pairing between non-Watson-Crick pairs such as 
A-G, as well as RNAs contain bulges, loops, and interactions between bases on separate 
strands creating  what is known as kissing loops (86,89,90). The diversity in base 
interactions found in RNA provides a wide diversity in folding and structure much to 
proteins (91). 
Furthermore, with the diverse folding of RNAs brings a variety of functionalities 
and actions. Traditionally, RNA is considered as a temporary intermediate of DNA for 
the translation of proteins; however, it is now well understood that RNA holds many 
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functionalities within the body and non-coding RNAs play important roles through gene 
expression and cell functionality. Such examples of these RNAs are pRNA of the Phi29 
bacteriophage, ribozyme (92-94), riboswitch(95,96), small interfering RNA (siRNA) (97-
99), micro RNA (miRNA) (100-102), ribosomal RNA (rRNA) (103-106), small nucleolar 
RNAS (snoRNA) (107-109), small nuclear RNA (snRNA) (110,111), and RNA aptamer 
(32,33). The simplistic design, yet diverse structuring and functionality of RNA has made 
it attractive to many scientist for applicational uses such as the treatment of cancers and 
viral infections. Due to the nature of RNAs, RNA nanotechnology provides several 
benefits over competing nanotechnologies utilizing proteins, DNA, and polymers 
(91,112): 1) as stated earlier, RNA can be produced with defined shape and stoichiometry 
as well as high reproducibility (12,86-88). 2) RNA can target specific cell groups by 
targeting cell surface receptors through the use of RNA aptamers, motifs that have 
specifically been selected for specific binding to chemical or protein ligands, without 
inducing antibody production, allowing for repeated delivery and therapy (113-115). 3) 
RNA nanoparticles that have been produced have a size range of 10-50 nm, the perfect 
size to be retained within the body and pass through leaky blood vessels in cancer tumors 
by Enhanced Permeability and Retention (EPR), as well as cell membranes by cell 
surface receptor endocytosis (66-68). 4) RNA can be created to harbor multiple 
therapeutic elements by utilizing branch scaffolds (98,116-119) and bottom-up 
construction (86,97). 5) RNA is known to have a higher thermostability over DNA with a 
higher melting temperature and more negative Gibbs free energy of formation (120,121). 
6) RNA materials have gained FDA approval due to their known exact known size and 
chemical makeup compared to other nanotechnologies  (91). 
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RNA scaffolds 
Since the original development of the tunable Phi29 packaging RNA (pRNA) 
nanoparticles several other RNA based nano-platforms have been produced. The Guo lab 
has continued their work on the Phi29 pRNA system, most notably with the three-way 
junction (3WJ) motif composed of three short oligo strands that has been proven to be 
thermodynamically stable (87,122). The 3WJ has since been used as a building block to 
produce the pRNA X-way motif (123); varying shapes including triangles, squares, and 
pentagons (124-127); and further 3D arrays from the resulting shapes. Additionally, Luc 
Jaegar first developed a building block coined as TectoRNAs that utilized looped regions 
between RNA strands for base pairing to build nanostructures (89). From the TectoRNAs 
a variety of structures have been built including tectosquares, Jigsaw puzzles, nancubes, 
and nanorings (88,128-131). Similarly Thomas Hermann has developed a self-assembling 
square composed of an RNA backbone (132) and Saito’s group has created a triangle 
RNA scaffold (133). Recently, Paula Hammond has developed an RNA microsponge that 
is capable of uptaking siRNAs for delivery (38,134). These RNA nanoparticles have laid 
the foundation of scaffold that can be used for the inclusion of RNAi components for the 
treatment of diseases (38,87,123,134-142). 
Elucidation and modeling of thermodynamic parameters of nucleic acids 
 The formation of RNA nanoparticles from multiple strands is depended on the 
formation of base pairing between or within singular strands. This assembly process is 
governed by thermodynamics, which has since been proven to be sequence dependent. 
Extensive studies have been completed looking at the thermodynamic contributions of 
each RNA and DNA sequence, which in turn developed nearest neighbor parameters. 
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Thermodynamic parameters during the folding and melting of RNA and DNA 
duplexes has been long studied using various sequences. Originally, duplex interactions 
of DNA was studied to derive thermodynamic parameters that lead to the modeling of 
nucleotide contributions in folding energy landscapes (143,144). This work resulted in 
the development of nearest neighbor predictions, in which thermodynamic parameters 
could be predicted by the sequence of DNA. RNA models were then created in a similar 
fashion (145-147), that then led to the studying of RNA/DNA hybrid duplexes (120). 
While these initial studies were very informative, the predictive models were limited to 
duplex structure, whereas RNA is known to fold into diverse structures with branches, 
bulges, and looped regions. In looking at several junctions and looped regions, Doug 
Turner was able to elucidate thermodynamic energies for RNA three- and four-way 
junctions (3WJ, 4WJ) (148).  
From these fundamental studies, thermodynamic experiments were expanded to 
study the overall thermostability between nucleic acid species. Lesnik and Freier first 
compared 14 sequences ranging from 9 up to 21 base pairs in length composed of DNA 
and RNA, along with each of the hybrid structures (RNA/DNA duplex) (149). From their 
studies, it was found that 13 of the 14 RNA sequences displayed melting temperatures, 
Tms, higher than the corresponding DNA sequences. In nucleic acid studies, melting 
temperature is defined as the temperature in which 50 % of the nucleic acid strands are 
assembled into motif and 50 % are in single strand states. Furthermore, the same 13 of 14 
sequences displayed the more favorable, more negative Gibbs free energy (ΔG°).  The 
ΔG° is the release (negative) or consumption (positive) of energy by the nucleic acid 
strands when folding into their motifs; a negative value indicated energy is being released 
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and is therefore spontaneous, the lower the value the more spontaneous the reaction will 
be. The one exception to the study was a sequence with a repeat of A-T base pairing. 
Several additional studies have been published on comparing thermostabilities and 
folding energy levels of RNA and DNA sequences (150-153). Again from each of these 
studies, it was concluded RNA produced a more negative ΔG° and more positive Tm over 
the same DNA sequence. The widespread studies of relative stability of RNA has shown 
it provides a more favorable folding landscape by assembling more spontaneously and 
displaying a higher overall stability with the increased melting temperature over DNA. 
Furthermore, from the derived nearest neighbor calculations and studying known 
RNA motifs and structures, several computational programs have been developed to 
predict the folding of RNA motifs and their relative energy landscapes for both folding 
and denaturing. Using energy landscape predictions, programs such as mFold (154), 
UNAfold (155), and RNAfold (154,156) have been developed to predict the secondary 
structuring of RNA motif leading to predictive base pairing. Moving from secondary 
interactions to tertiary and quandary predictions has proven to be much more difficult. 
RNA structural studies have thus been conducted by Eric Westhof (157-160), Neocles 
Leontis (89,90,157,161-163), and David Lilley (164-167). Such studies have created 
databases of RNA motifs that are now used for the predictive folding and interactions of 
RNA sequences (168-171). 
Importance of thermodynamics and kinetics in RNA nanotechnology 
 Due to the fact that RNA nanoparticles rely on hydrogen bonding between base 
pairing to keep the nanoparticle together, folding thermodynamics and kinetics are 
imperative for nanoparticle stability. Together kinetics and thermodynamics describe the 
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ability and speed of the RNA motif or nanoparticle to fold, along with its overall stability. 
In nanoparticles design, the folding mechanism is crucial, in that a central motif that folds 
rapidly and spontaneous with favorable thermodynamics is desired. Additionally one 
must examine the folding energies to examine the concern of side products is 
minimalized, in order to produce as pure of a product as possible. In nanotechnology, 
creating particles of defined shape and size with high reproducibility is paramount in 
going through FDA approval. Additionally particle thermodynamic stability is an 
absolute key in nanoparticle design and construction. In looking at in vivo applications, 
nanoparticles will be subjected to dilute concentrations and elevated temperatures of the 
body of 37 °C. These conditions will test the stability of base-paired RNA motifs in 
which dissociation is not only unacceptable, but a serious concern. Nanoparticles must be 
tested to be stable at temperatures and concentrations that will be seen in vivo to ensure 
stability of the particle and therapeutic as well as proper delivery of the therapeutic agent 
to the target. As shown above through the nearest neighbor modeling, thermodynamic 
stability of RNA duplexes and structuring is highly dependent on both the sequence and 
oligo length. Therefore full characterization of folding and stability of nanoparticles is 
necessary for the advancement of the field to in vivo applications. 
 
 
 
 
Copyright © Daniel William Binzel 2016 
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Chapter 2: Thermodynamic Analysis of Phi29 pRNA-3WJ 
This chapter was reproduced (with some modification) with permission from Binzel DW, 
Khisamutdinov EF, Guo P. “Entropy-Driven One-Step Formation of Phi29 pRNA 3WJ 
from Three RNA Fragments.” Biochemistry, 2014. 53 (14), 2221-2231. DOI: 
10.1021/bi4017022. Copyright 2014 American Chemical Society. Special thanks to Dr. 
Emil F. Khisamutdinov for help in preparation of data for figures 2.3, 2.5, and 2.6A and 
Zhengyi Zhao in preparing figure 2.1A. 
 
INTRODUCTION: 
Since the proof-of-concept in 1998 (12), RNA nanotechnology has been emerged 
as a popular field (86,91,128,157,159,172-175). RNA has the simplistic chemical 
characteristics of DNA, and the complex folding and functionality of proteins (91). These 
attributes make RNA an ideal candidate for creating nanoparticles with diverse 
functionalities for targeting and treating cancer tumors and viral infections, as well as 
other applications in nano devices (12,38,86,87,118,123,176-182). RNA nanotechnology 
in therapeutics provides many advantages over current technologies (91,112): 1) RNA 
can be produced with defined shape and stoichiometry as well as high reproducibility 
(12,86-88). There are many modified nucleosides within RNA, but it is primarily 
composed of only four nucleic acid bases, allowing for simplicity in structure and 
predictable interactions between molecules and formation of structures. 2) RNA can 
target specific cell groups by targeting cell surface receptors through the use of RNA 
aptamers that function like protein or chemical ligands (113-115). These structures do not 
induce antibody production, allowing for repeated delivery and therapy (113). 3) RNA 
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nanoparticles that have been produced have a size range of 10-50 nm (66-68), the perfect 
size to be retained within the body and pass through leaky blood vessels in cancer tumors 
(69,183), as well as cell membranes by cell surface receptor endocytosis (68). 4) RNA 
can be created to harbor multiple therapeutic elements by utilizing branch scaffolds 
(98,116-119) and bottom-up construction, the development of nanoparticles through the 
design of subcomponents that then are used to assemble into the final product (86,97). 
Even with these advantages, RNA nanotechnology has been hindered because of the 
instability of RNA itself, specifically in vivo. Dissociation of complex without covalent 
bonds is an intrinsic property of molecules, e.g. RNA molecules, that are 
thermodynamically instable in nature (120,146,149,150,184-188). 
When RNA nanoparticles are delivered systemically to the body, the particles will 
exist in low concentrations due to dilution by circulating blood. Only those RNA particles 
that do not dissociate at low concentrations are feasible for therapeutic purposes that 
require systemic delivery. Furthermore, RNA can easily be degraded and cleaved by 
RNase found throughout the human body (112). Chemically modified nucleotides have 
been developed to combat the nuclease degradation. Specifically, 2′-F modified 
nucleotides have been shown to keep the original folding and functionality of the RNA 
molecules while significantly increasing the half-life (189). In order to overcome the 
instability issues and push the RNA nanotechnology field to progress further, a stable 
platform needs to be produced that can remain stable at low concentrations and high 
temperatures while resisting RNase degradation (87,123,177). 
Recently, a three way junction motif (3WJ) in the packaging RNA (pRNA) of the 
bacteriophage Phi29 dsDNA packaging motor was found to be ultra-stable (87). The 
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pRNA-3WJ produced a melting curve indicative of a low Gibbs free energy (ΔGº), the 
total energy that is either released or consumed by a system through a reaction or work, 
thus determining spontaneity of the system (190,191), as well as a high melting 
temperature (Tm). It has also been elucidated that the 3WJ is stable in ultra-low 
concentrations, as well as in 8 M urea, a common denaturing agent for nucleic acid 
structures. This junction serves as the central core of the pRNA and links the helical 
domain (192) to the interlocking looped regions (193), and allows for intermolecular 
interactions with other pRNA molecules (Fig. 2.1). The core can be formed from three 
individual RNA oligos with a high efficiency without the presence of metal ions, as many 
RNA motifs require the presence of metal ions, like Magnesium, for folding, assembly, 
and stabilization. Therefore, the pRNA-3WJ shows an initial sign of higher stabilization 
than many RNA motifs. It has been found that this junction can incorporate RNA 
functional moieties, such as receptor-binding aptamer (32,33), siRNA (97-99), ribozyme 
(92-94), miRNA (100-102), or riboswitch (95,96). Additionally, the resulting structures 
have the ability to keep the strong folding of the core, while retaining the functionality of 
the conjugated RNA moieties (87). Even with the strong stability of the 3WJ, it is still 
very much susceptible to degradation by RNases; therefore, chemical modifications to the 
RNA are required (64,186,195). The effects on the thermodynamic stability of the 
pRNA-3WJ core, though, are still unknown. 
Previously, thermodynamics of nucleic acids and their folding properties have 
been studied; however, the majority of the studies have been completed on RNA and 
DNA duplex sequences (120,143,144,146,149-151,153). An estimation of 
thermodynamic parameters for RNA 3- and 4WJ have been surmised (148) from studies  
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Figure 2.1. Background information for motor pRNA, pRNA three-way junction 
(3WJ). (a) The side-view of the hexametric structure of Phi29 DNA-packaging 
motor(194). Two bottom are side-view and top-view of the hexameric pRNA derived 
from X-ray crystallography(122). (b) Predicted secondary structure of the Phi29 
packaging RNA (pRNA) with the 3WJ motif outlined and the pRNA-3WJ. 
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completed using two piece designs by incorporating looped regions between helical 
branches. A gap has remained within the thermodynamic studies of nucleic acids 
regarding elucidating thermodynamic characteristics of multi-branched structures, i.e., 
multi-stranded motifs. Additionally the understanding of chemical modifications to the 
RNA backbone on RNA junctions has remained a mystery, and untouched. In order to 
understand the thermodynamic characteristics of such structures and comprehend the 
governing laws of motif folding, new methods must be developed to be able to see multi-
stranded interactions. 
Here we report the measured thermodynamic parameters for 3WJ complexes 
containing DNA, RNA, and 2′-F U/C modified RNA strands (Fig. 2.1), as well as hybrid 
complexes by means of comparison of their stability using a real time Polymerase Chain 
Reactions (rtPCR) machine and Temperature Gradient Gel Electrophoresis (TGGE). 
Results concluded that use of DNA strands weakened the structure of the pRNA-3WJ, 
while 2′-F modifications strengthened the RNA motif by elevating the transition 
temperatures and lowering ΔG°. More importantly, the data appears to show the 3WJ 
formed in a single step without displaying presence of dimer species, showing that all 
three strands of the pRNA-3WJ formed together into complex rapidly with the 
intermediate product undetectable. The assembly was also revealed to be entropy driven. 
MATERIALS AND METHODS: 
Oligonucleotides and assembly of 3WJs 
RNA, DNA, and oligonucleotides were obtained from Integrated DNA 
Technologies (IDT). RNA oligonucleotides containing 2′-F U/C modification were 
ordered from Trilink BioTechnologies. Assembly of 3WJs were performed by mixing 
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equimolar concentration of corresponding strands in TMS (50 mM TRIS pH = 8.0, 100 
mM NaCl, 10 mM MgCl2) buffer, heating to +80 °C, and slowly cooling to +4 °C at a 
rate of 2.0 °C/min for a total of 37 minutes. The 3WJ formations were assayed on a 12% 
native PAGE TBM running buffer (89 mM Tris, 200 mM Borate acid, and 5 mM MgCl2) 
ran at 100 V at 4 °C for 90 min. Gels were stained with Ethidium Bromide (EB) and 
imaged using a Typhoon (GE). 
KD measurements 
Apparent equilibrium dissociation constants (KD) for 3WJ formations were 
determined by titration over a range of concentrations from 0.1 nM to 512 nM, as 
previously described (88,196). Concentrations of the 3WJs were calculated using the 
absorbance of UV light at 260 nm using a Nanodrop 2000 (Thermo Scientific) using an 
extinction coefficient of 40 µg/ml and 50 µg/ml for RNA and DNA, respectively. Briefly, 
fixed amounts of [32P] ATP 5′-end labeled 3WJb strands of RNA, DNA, and 2′-F 
modified RNA (0.1 nM final) were mixed with variable amounts of unlabeled 3WJa and 
3WJc strands RNA to make the indicated final concentration (0.1 nM to 512 nM) of each. 
The resulting 3WJs were then heated to 80 °C for 3 min in TMS buffer and slowly cooled 
to 4 °C. The resulting gel shifts were measured using Image J software and interpreted 
with the program Origin 8.0. The fractions (f) for each trimer forming complex was 
calculated by dividing the corresponding quantified values for trimers by the total sum of 
values for all complexes (monomer, dimer, and trimer) presented in the corresponding 
lane. The combined data from several independent measurements were subjected to non-
linear curve fitting using the equation: 
                  (2.1) 
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where Ct is the total concentration of RNA strands in each lane and f is the fraction of 
3WJ complex to total concentration. 
In calculating the Ct, the concentration of the labeled 3WJb strand was not 
included, as it was in trace amounts and negligible to the concentrations of 3WJa and 
3WJc. The Ct at equilibrium was calculated by interpolation of the fraction (f) at 50%. 
These values were then in turn used to calculate the equilibrium KDs (191). Marky et al. 
described this calculation using changing temperature to reach equilibrium, thus requiring 
equal concentrations of each strand; however, equilibrium was reached here by varying 
concentrations, as previous performed (88,196), thus not requiring equal concentrations 
of each strand. 
Real time PCR annealing curves of 3WJ complexes 
Each synthesized pRNA-3WJ strand (3WJa, 3WJb, 3WJc) was mixed at equimolar 
concentrations in the presence of 1x SYBR Green II dye (Invitrogen) at equal molar 
ratios of 10 μM to create a 3WJRNA, 3WJDNA, and 3WJ2′-F. SYBR Green II dye is a 
reporter dye with higher specificity for RNA, but shows binding to both DNA and RNA 
bases (197). Using a Roche Lightcycler 480 real time PCR machine, with accurate 
readings of temperatures to ± >0.25 °C, samples were heated to 95 °C for 5 min for an 
initial denaturing period and then slowly cooled at a rate of 0.11 °C/sec until 20 °C. The 
Roche Lightcycler 480 was able to detect the fluorescence levels, thus monitor the 
formation of the 3WJ cores. All samples were completed in triplicate to ensure accuracy 
of the annealing temperatures and profiles. Samples were then subjected to 
electrophoresis on a 12% polyacrylamide gel to ensure the formation of the 3WJs. All 
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hybrid structures of the pRNA-3WJ core were created using a mix of RNA/DNA, 
RNA/2′-F RNA, or DNA/2′-F RNA in the same method described as above. 
TGGE and thermodynamic parameters  
All 3WJ hybrids were assembled as described above. The Temperature Gradient 
Gel Electrophoresis (TGGE) system from BiometraHmbGh, Germany was used in this 
study. Temperature was varied perpendicular or parallel to the electrical current. All 
experiments were performed in TMS running buffer. The RNA bands were detected in 
native 15% gel by total RNA stain using Ethidium bromide (EB). The concentrations of 
3WJs were typically 10 μM. All varieties were run a minimum of three times to ensure 
accuracy of measurement. 
Various concentrations of preassembled pRNA-3WJs covering 1,000 fold 
dilutions from 10 μM to 0.016 μM were subjected to the perpendicular TGGE for 
thermodynamic parameter calculations. 3WJ bands were detected with radiolabeled 3WJc 
strands at the 5′-end using γ-32P ATP (Perkin Elmer). A linear temperature gradient of 
ΔT = 44 °C was applied perpendicular to the electric field. The gels were run for 1 hr at 
constant 80 V, dried, and exposed to phosphoroimaging screen overnight. Gels were then 
visualized on a Typhoon (GE), and Image J software was used to quantify the area of 
bands on each lane by plotting intensity of each band intensity and integrating the area 
under the curve for each band. Background signal of each lane immediately surrounding 
the band of interest from the gel was subtracted and removed from the band intensity and 
not included in calculations. The fraction of 3WJ bands were obtained by subtracting the 
area of melted bands from the trimer band. Melting temperatures were then calculated 
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from a plot of 3WJ fraction (f) vs. temperature, with f = 0.5 (50%) corresponding to the 
Tm. 
Calculation of Thermodynamic parameters  
Tm values at different concentration of 3WJs were used to calculate 
thermodynamic parameters. van’t Hoff plots were generated by plotting the Tm versus the 
concentrations of non-self complementary three molecular strands according to a 
previous method (191): 
   
∆ °
ln ∆
°
∆ °
              (2.2) 
where R is the gas constant 1.987 cal mol-1 K-1 , Ct is the total concentration of each 
3WJs, and ΔH° and ΔS° are enthalpy and entropy changes, respectively. Under this 
method of calculation, the assumption is made that the heat capacity remains unchanged 
throughout the entire melting profile. 
Fluorescence of pRNA-3WJ-MG aptamer 
The assembled unmodified and 2′-F A/C modified 3WJs (1 μM) were mixed with 
Malachite green triphenylmethane (2 µM), a non-fluorescent dye that only fluoresces 
when bound to the Malachite green binding aptamer, in binding buffer containing 100 
mM KCl, 5 mM MgCl2, and 10 mM HEPES (pH 7.4) and incubated at room temperature 
for 30 min. The fluorescence was measured using a fluorospectrometer (Horiba Jobin 
Yvon; SPEX Fluolog-3), excited at 615 nm, and scanning from 625 to 800 nm for 
emission (198). 
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RESULTS AND DISCUSSION: 
Assembly of the three-way junctions 
pRNA three way junctions composed of RNA (3WJRNA), DNA (3WJDNA), and 2′-
F U/C modified RNA (3WJ2′-F) were assembled using equimolar concentrations of each 
strand of the 3WJ. The formation of the pRNA-3WJs in each of the species was 
confirmed by 12% native PAGE (Fig. 2.2). A step-wise assembly through the 
polyacrylamide gel was observed between the monomer to dimer, and finally to the fully 
assembled trimer band indicating the formation of 3WJs. The assembled RNA, DNA, and 
2′-F 3WJs products resulted in high yield (> 90%). Any side product is assumed to be 
contributed to slight mismatch in strand concentrations loaded during assembly, 
preventing all nucleic acid strands from forming into the 3WJ complex. The data are in 
agreement with previously reported results of RNA-3WJ assembly (87).  
Dissociation constants (KD) measurements of the 3WJs 
The KD values of nucleic acids formation are directly related to their stabilities as 
more stable complexes require lower concentrations of the components for self-assembly 
resulting in a lower KD value. We measured the apparent dissociation equilibrium 
constants for RNA, DNA and 2′-F modified RNA 3WJ complexes (Fig. 2.3). For the 
3WJRNA and 3WJ2′-F the KD values were found to be 11.4 and 4.5 nM, respectively. For 
the 3WJDNA complex this value was about five times higher (47.7 nM). This indicates that 
3WJ2′-F and 3WJRNA were the most stable complexes, and the least stable was 3WJDNA. 
These results demonstrated that the incorporation of enzymatically resistant DNA or 2′-F 
modified RNA strands into the RNA 3WJ motif could increase the resistance of the 
complex to RNases. However, while the DNA strands incorporation decreases the  
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Figure 2.2. Assembly of pRNA-3WJ core structures. 12% polyacrylamide gels in 
native conditions displaying the stepwise assembly of the 3WJ2′-F, 3WJRNA, and 3WJDNA. 
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Figure 2.3. Dissociation constant measurements. Electrophoeretic Mobility Shift 
Assay (EMSA) of 32P-labeled 3WJb (constant concentration) assembling with increasing 
concentrations of 3WJa and 3WJc for RNA, 2′-F RNA, and DNA on 12% polyacrylamide 
gels in native conditions. Plot of percentage of 3WJ formed vs. total concentration to 
solve for KD of each 3WJ. 
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stability, the 2′-F modified RNA increases the stabilization of the 3WJ complex, as 
shown by the lower dissociation constant compared to the 3WJRNA. Therefore, if a 
nanoparticle were needed to be constructed with an alternative melting temperature than 
the native 3WJRNA, the stability and properties of 3WJRNA motif can be tuned by 
alternating the ratio of 2′-F modified RNA and DNA strands to either increase or 
decrease the stability, respectively. 
 Determination of the formation of complex and Ta of DNA, RNA, and 2′-F RNA-3WJs by 
rtPCR machine 
The thermostability of 3WJs complexes were compared by measuring their 
fluorescence intensities as a function of temperature in the presence of SYBR Green II 
dye on a Roche 480 Lightcycler to obtain Ta (87). The annealing transitions in Fig. 2.4A-
C show that the mixture of three strands (3WJa, 3WJb, and 3WJc) produced the highest 
annealing temperature compared to any monomer or dimer formation. Within the 
assembling profile, the slope of the transitions directly correlates with ΔG°, as the steeper 
slope results in a more negative ΔG° values (190,191). These results showed that the 
assembly of the 3WJ was preferred over any dimer formation of any two strands in each 
of the three species: RNA, DNA, and 2′-F modified RNA. 
From each of the transitions obtained by the Roche 480 Lightcycler, the curves of 
the each of the completed 3WJ structures were compared (Fig. 2.4D). The 3WJ2′-F was 
the most stable with Ta = 69.8 °C, the 3WJRNA was the next stable at 59.3 °C, and the 
3WJDNA had the lowest where Ta = 48.9 °C. These results correlated with literature 
reported values of overall thermostability for nucleic acids, and followed the order of 
stability: 2′-F RNA > RNA > DNA (150,151,199). Surprisingly, from the assembly 
profiles of the pRNA-3WJ species, a single annealing temperature was seen, not two.  
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Figure 2.4. Assembly curves produced from the Roche 480 Lightcycler using SYBR 
green II reporter dye. (a) 3WJRNA, (b) 3WJDNA, (c) 3WJ2′-F, and each of the components 
of the 3WJs. (d) The three 3WJ species directly compared, showing the differences in 
melting temperatures (Ta). 
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This is evidenced by the single slope to the transition profile and hinting that the 3WJ is 
forming rapidly with all three strands producing no by-products; whereas, a two-step 
association would display a plateau within the melting curve itself or two individual 
sloped regions, resulting in two annealing temperatures. These results show the three 
stranded motif forming together, and a dimer species was undetectable due to the rapid 
3WJ formation. This rapid formation from three fragments to form the pRNA-3WJ is 
highly beneficial due to the fact that it allows a high yield of assembly, while permitting 
for the construction and assembly of RNA nanoparticles without creating side products as 
a result of the dimer formation. 
Comparison of stability between DNA, RNA, and 2′-F RNA-3WJs by TGGE 
TGGE is common technique to measure Tm of large and complex nucleic acids 
(88,200,201). This approach has an advantage over the real time PCR in that it can be 
applied to directly measure the Tm of RNA complexes as fractions of RNA versus 
temperature with no intercalation dye required. 
Melting temperatures of 3WJ complexes were determined by measuring the 
decrease in the yield of 3WJs versus temperature (Fig. 2.5). A temperature gradient was 
applied perpendicular to the electrical current, with an increasing temperature that 
resulted in the melting of the structures in the later lanes. Here, the percent 3WJ complex 
was compared to dimer and monomer formations. Tm were determined as 50% of 3WJ 
remaining. Any remaining dimers were not considered as a complex, as it was not 
complete 3WJ formations. From the resulting gels, melting temperatures were derived for 
the 3WJ2′-F, 3WJRNA, and 3WJDNA as 66.5 °C, 57 °C, and 35.2 °C, respectively. The 
melting temperatures for the two RNA species were within the range of error from the Tm  
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Figure 2.5. Representative 15% native TGGE with temperature gradient 
perpendicular of the electrical current. (a) 3WJ2′-F, (b) 3WJRNA, and (c) 3WJDNA; total 
3WJ concentration in each lane = 10 µM. (d) and (e) are control gels showing migration 
of 3WJRNA (d) before reaching its Tm in the temperature range of 20-40°C and migration 
of 3WJDNA (e) in the temperature range of 40-70 °C that is over its Tm. The 3WJ bands 
were detected by total nucleic acid stain with EB.  
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found by the fluorescence melting curves, but there was a large difference in Tm between 
the two methods for the 3WJDNA. This difference between these two methods was 
presumably due to differing affinities of SYBR Green II to DNA and RNA stacking bases 
(197). Nevertheless, both methodologies produced data that allowed direct comparison of 
the stability among 3WJ complexes, and demonstrated the trend that 2′-F RNA had a 
higher melting temperature than RNA, and RNA had a higher Tm than DNA. 
Within the TGGE melting gels, the dimer species were again undetected in the 
melting curves in the 2′-F RNA and RNA 3WJ species, further pointing to the possibility 
of the unusual assembly pathway. However, the 3WJDNA seemed to display a dimer 
intermediate, which was previously not seen from the PCR melting profiles. We believe 
that this difference between the two temperatures is due to the fact that the TGGE 
showed the melting profile, while the PCR curves showed the association of the 
molecules. Therefore the TGGE system of the DNA species was dissociation down to a 
dimer then monomer, possibly due to the fact that DNA was not the natural species of the 
pRNA-3WJ and forced the motif into an unnatural conformation. Furthermore, any dimer 
species that is seen in radiolabeled gel analysis can be attributed a slight concentration 
mismatch between unlabeled individual strands, and were therefore ignored. 
Thermodynamic parameters for 3WJs formation 
Non-self complementary nucleic acids usually exhibit a linear correlation Tm and 
RNA concentration, as the Tm increased with the increase in nucleic acid strands 
concentration (146,148,202). The TGGE approach was further applied to measure Tm of 
3WJ species as a function of concentration using ~1,000 fold dilution of the 3WJRNA, 
3WJ2′-F, and 3WJDNA complexes from 10 μM to 0.016 μM (Fig. 2.6A). Tms were  
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Figure 2.6. Calculation of thermodynamic parameter for 3WJs formation. (a) 
Representation of native 15 % TGGE for the 3WJ complexes at the lowest concentration 
(0.016 μM in each lane). The radiolabeled C strand of corresponding 3WJ complexes 
indicated with asterisk ‘*’. Lanes 3WJc* and 3WJc*+3WJa served as controls for 
monomer and dimer location. (b) Melting temperature profiles of RNA, 2′-F RNA, and 
DNA 3WJs obtained after quantification of the corresponding band from the 
perpendicular TGGE at various concentrations. (c) Plots of Tm vs. 3WJ concentrations 
(van’t Hoff analysis) evaluated from melting curves of the 3WJ complexes obtained at 
different strand concentrations.  
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calculated by finding the temperature at which 50% of the nucleic acids were in trimer 
formation compared to the total concentration of the bands observed. 3WJ Tms were used 
to calculate thermodynamic parameters for three components of non-self complementary 
sequences, according to Marky et al. (191). The typical van’t Hoff plots for 3WJ2′-F, 
3WJRNA, and 3WJDNA are represented in figure 2.6C. From the obtained ΔH° and ΔS° 
parameters the ∆G°37 was calculated using equation 2.3: 
∆ ° ∆ ° 310.15 ∆ °          (2.3) 
where ΔH° and ΔS° are enthalpy and entropy, respectively, and K is the abbreviation for 
Kelvin. All thermodynamic parameters are summarized in table 2.1. Here the data 
produced a near linear trend lines with r2 values very near 1.00. Due to this little error is 
seen in calculating melting temperatures, samples were repeated in a selective fashion 
due to the high number of gels that would be needed. The repeated experiments allowed 
for calculation of error in the thermodynamic parameters which remained low. The 
results indicated that the most thermodynamically stable was the 3WJ2′-F (ΔG°37 = -36 
kcal/mol) complex, followed by 3WJRNA, (ΔG°37 = -28 kcal/mol), and the 3WJDNA 
(ΔG°37 = -15 kcal/mol). Based on the parameters of free energy change for RNA and 2′-F 
RNA-3WJ assemblies, it can be determined that the energy for these complexes were 
favored two-fold compared to the 3WJDNA. The 3WJDNA displayed a more favorable 
decreased enthalpy value of ΔH° = -220 kcal/mol, compared to 3WJ2′-F (ΔH° = -200 
kcal/mol), and 3WJRNA (ΔH° = -170 kcal/mol). However, the comparison of entropy 
parameters resulted in a significant increase for the RNA and 2′-F RNA complexes. The 
two RNA species resulted in more negative free energy changes, yet had higher 
enthalpies when compared to DNA. This data combined with the increased entropy  
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Table 2.1. Thermodynamic parameters for 3WJs 
formation.a 
  1/Tm vs Log (Ct) 
3WJs 
ΔG°37 
(kcal/mol)
ΔH° 
(kcal/mol) 
ΔS°37 
(e.u.) 
Tmb 
(°C) 
2'-F RNA -36 ± 0.45 -200 ± 5.7 -520 ± 17 72.1 
RNA -28 ± 0.58 -170 ± 13 -440 ± 39 60.4 
DNA -15 ± 0.71 -220 ± 25 -650 ± 83 35.2 
aParameters derived from 15% native TGGE. 
bTm values for 3WJ strand concentrations of 10-6 M 
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values of the RNA species indicated that the thermodynamic stabilities of the 3WJRNA 
and 3WJ2′-F were entropy-driven (Table 2.1). 
The findings of more negative ΔG° values for 2′-F RNA and RNA are consistent 
with other studies comparing helical DNA, RNA, and 2′-F RNA (150,151,153,199,203). 
However, the notion that was RNA entropically driven, compared to DNA in helical 
structures appeared less unanimous as the majority report RNAs to be less entropically 
favored and that folding is normally driven by a lower enthalpy value (150,151,153,203). 
Here it is believed that the 3WJDNA provided a more rigid structure, producing a lower 
internal energy or ΔH compared to the RNAs; however, the flexibility of the RNAs 
provided more disorder, thus giving strong stability, ease of folding, and a more negative 
ΔG°. This entropy driven assembly combined with the one step assembly expresses the 
unusual thermodynamic characteristics of the pRNA-3WJ. 
Analysis of 3WJ hybrid formations and thermostability 
The hybrid composition (2′-F RNA/RNA; RNA/DNA; DNA/2′-F RNA) within 
the RNA 3WJs are of great interest due to their ability to maintain the diverse 
functionality of structured RNA molecules, while incorporating the chemical stability of 
2′-F RNA and DNA. To test for hybrid 3WJ viability, the 2′-F RNA/RNA; RNA/DNA; 
DNA/2′-F RNA hybrids of the 3WJs complexes were characterized by parallel TGGE 
and fluorescence melting temperature experiments. Using the TGGE, a temperature 
gradient was applied in parallel to the electrical current (Fig 2.7). As the samples 
migrated through the gel, the temperature increased from 20 °C to 70 °C; therefore, 
melting the hybrid structures as they migrated further into the gel. A less stable 3WJ 
complex migrates further as the elevated temperature melts the structure to smaller single  
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Figure 2.7. Native 15% TGGE of some hybrid 3WJs with temperature gradient in 
parallel of the electrical current. As the 3WJs migrated into the gels, weaker structures 
melted due to the elevating temperatures, resulting in a more rapid migration; stable 
structures migrated at slower rates. Concentration of hybrids in each lane = 10 µM, the 
bands were detected by total nucleic acid stain with EB. (a) Hybrids analyzed in linear 
temperature gradient of 20 – 40 °C and (b) the same samples but the temperature range 
was 40-70 °C.  
  
36 
 
strands, thus causing an increased rate of migration and separating the stable hybrids 
from unstable hybrids. 
The TGGE analysis demonstrates that each hybrid structure forms correctly and is 
stable at lower temperature ranges 20-40 °C (Fig. 2.7A). However, at a higher range of 
40-70 °C the RNA/DNA and DNA/2′-F RNA-3WJ hybrid structures melted, resulting in 
a more rapid migration rate compare to 2′-F RNA/RNA hybrids (Fig. 2.7B). This direct 
comparison between hybrid stability demonstrates weakness in the thermostability of 
hybrids involving DNA strands. In addition, the 3WJs hybrids followed the general trend 
that more strands with 2′-F modifications equate to a higher stability overall. These 
results were further confirmed by the melting temperatures produced for each hybrid on 
the Roche 480 Lightcycler as shown in figure 2.8 and table 2.2. Combining the TGGE 
gels along with the annealing temperatures provided from the fluorescence melting 
curves, the data further supports the findings that 2′-F modifications strengthen the 
thermostability of the pRNA-3WJ while DNA substitutions only weaken the 3WJ 
complex. In this case, even limited modifications lead to a difference in the 
thermostability. 
MG-aptamer functionality assay and stability 
In order to ensure that the added stability of the 2′-F modifications to the pRNA-
3WJ was true for a functional, more complex RNA nanoparticle, a fluorescence assay 
was performed. The pRNA-3WJ used in this study harbored the Malachite Green (MG) 
RNA aptamer that binds to Malachite green triphenylmethane dye causing the chemical 
to fluoresce (204). Malachite green itself emits very low fluorescence; therefore, a change  
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Figure 2.8. Comparison of pRNA-3WJ hybrid structures. Assembly curves produced 
from the Roche 480 Lightcycler of the pRNA-3WJ (a) RNA/DNA hybrids, (b) RNA/2′-F 
RNA hybrids, and c) DNA/2′-F RNA hyrbids. 
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Table 2.2. Annealing temperature for 3WJ hybrid formation.a  
2′-F RNA to RNA  Ta (°C) RNA to DNA  Ta (°C) DNA to 2′-F RNA Ta (°C) 
a2'-F/b2'-F/c2'-F  69.8±2.0 aRNA/bRNA/cRNA  59.3±1.7 aDNA/bDNA/cDNA  48.9±3.2
a2'-F/b2'-F/cRNA  65.4±0.1 aRNA/bRNA/cDNA  42.6±2.2 aDNA/bDNA/c2'-F  48.4±1.6
a2'-F/bRNA/c2'-F  64.1±0.2 aRNA/bDNA/cRNA  48.6±1.5 aDNA/b2'-F/cDNA  51.6±0.4
aRNA/b2'-F/c2'-F  65.5±0.2 aDNA/bRNA/cRNA  53.1±0.1 a2'-F/bDNA/cDNA  47.2±1.5
a2'-F/bRNA/cRNA  62.1±0.1 aRNA/bDNA/cDNA  44.5±2.6 aDNA/b2'-F/c2'-F  59.5±0.2
aRNA/b2'-F/cRNA  62.7±0.2 aDNA/bRNA/cDNA  45.9±2.4 a2'-F/bDNA/c2'-F  52.4±0.6
aRNA/bRNA/c2'-F  61.9±0.4 aDNA/bDNA/cRNA  47.3±0.4 a2'-F/b2'-F/cDNA  51.2±1.8
a Annealing temperatures calculated at 10 µM total strand concentration in TMS 
buffer.  
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in the fluorescence can be used to confirm binding and complexation between the RNA 
aptamer and chemical (69,198,204,205). 
It has been previously shown that the MG aptamer remains active in binding 
when nucleotides remain unmodified, as well as when using 2′-F cytosine and adenine 
modified nucleotides (198). Therefore we constructed the pRNA-3WJ-MG using 
unmodified RNA strands and 2′-F A/C modified RNA strands (see Fig. 2.9A for 2D structure). 
The resulting particles were then tested for binding to the MG to show the folding and 
functionality of the MG aptamer by measuring its fluorescence emissions (Fig. 2.9B). Both 
nanoparticles showed almost identical fluorescence values indicating the formation of correctly 
folded structures. 
Further we used real time PCR to measure the Ta of pRNA-3WJ-MG and 3WJ-
MG2′-F constructs (Fig. 2.9C). The annealing curves show that the 2′-F A/C modified 
3WJ resulted in the annealing temperature of 69.7 °C, higher than unmodified RNA 
variant with Ta value of 62.8 °C. This is consistent with the trend of increased RNA 3WJ 
stability using 2′-F modifications. Thus, the data demonstrate the effectiveness of the 
fluorine modifications regardless of the complexity of the structure, while retaining the 
functional conformation of the pRNA-3WJ. 
CONCLUSIONS: 
In this chapter we obtained thermodynamic parameters for the pRNA-3WJ using 
real time PCR and TGGE approaches. It was seen that the three fragments existed either 
in 3WJ complex or as monomers, with the intermediate of dimers almost undetectable. It 
seems that the three fragment can lead to the formation of 3WJ complex efficiently 
within a rapid time. It is also found that the formation of the three-component complex  
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Figure 2.9. Thermo-stability of functional pRNA-3WJ nanoparticle. (a) Secondary 
structure and sequence of the 3WJ-MG aptamer. (b) Fluorescence emission of 3WJ-MG 
aptamer, demonstrating binding of the nanoparticle to MG in both RNA and 2′-F species. 
(c) Melting curves for the 3WJ-MG and 2′-F A/C RNA-3WJ.  
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was governed by entropy, instead of enthalpy, as usually found in RNA complexes. By 
combining this beneficial assembly with the improved thermodynamic characteristics by 
2′-Fluoro modifications to the pRNA-3WJ stable RNA nanoparticles can be constructed 
with a high yield of over 90%for the treatment of cancers and viral infections. 
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Chapter 3: Kinetic Evaluation of pRNA-3WJ Folding 
This chapter (with some modification) is in submission at Journal of Biological 
Chemistry. Special thanks to Dr. Janice Ortega for help and assistance in preparation of 
data for figures 3.2, 3.3, 3.5 and Dr. Emil F. Khisamutdinov for help in preparation of 
data for figure 3.4. 
 
INTRODUCTION: 
The field of RNA nanotechnology has recently undergone rapid expansion mainly 
due to the fact that RNA has the simplicity characteristic of DNA yet the versatile 
functionality of proteins (86,91,128,157,159,172-175). With the combination of the 
advantage of these two materials, RNA can easily be designed and constructed through 
bottom-up construction and plays diverse roles (86,97). The wide-ranging functionalities 
of RNA makes it a prime candidate for applications in sensing operates (206), logic gate 
computional parts (207-214), imaging reagents (215-218), nano-electro-mechanical 
devices (219), and therapeutics including the delivery, specific targeting, and treatment of 
cancer and viral infections (12,38,86,87,118,123,176-182). The use of RNA as a delivery 
vehicle provides several benefits over other systems and technologies. Firstly, RNA 
nanoparticles can be produced with known stoichiometry and high reproducibility (12,86-
88,124-126), as RNA is composed of simple building blocks with predictable secondary 
structure. RNA aptamers can be employed for specific targeting of cell groups through 
binding to cell surface receptors much like a protein ligand or antibody (113-115). 
Furthermore the replacement of protein targeting reagents with nucleic acids prevents the 
induction of antibody (113), allowing for repeated administration. RNA nanoparticles are 
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typically between 10 and 50 nanometers in size meaning they are retained in the human 
body, yet are small enough to pass through cell membranes through endocytosis (66-
68,68,69,125,126,183). In in vivo testing RNA nanoparticles have shown favorable 
pharmacokinetic and biodistribution properties, as they are able to avoid accumulation in 
healthy organs and tissues with efficient retention in tumors (87,123), which is further 
expanded upon in Chapter 4. Additionally, RNA possesses unique in vivo attributes such 
as transcription, termination, splicing and processing allow for in vivo RNA production; 
riboswitches (95,96) and ribozymes (92-94) result in in vivo processing and possible 
assembly into nanoparticles in cell for special function such as intracellular computation 
(207-214)}; RNA can self-assemble without external forces (208); and RNA is stable in 
acidic environments allowing for survival in endosome (112). Even with these 
advantages, RNA nanotechnology still has many hurdles that it must overcome in order 
to be employed in therapeutics. Most notably, RNA is known to have stability issue and 
is prone to degradation by RNase that has since been solved through backbone 
modifications, such as 2’-Fluoro (189,220), 2’-OMethyl (221), or Locked nucleotides 
(222). The dissociation of the self-assembled RNA nanoparticles at low concentrations 
and elevated temperatures at in vivo environments makes it obligatory to address the 
dynamic and kinetics issues in RNA nanoparticle assembly (120,146,149,150,184-188). 
Recently a novel ultra-stable RNA motif was found in the packaging RNA 
(pRNA) of the Phi29 dsDNA packaging motor (Fig. 3.1), that has since diminished the 
concerns of RNA nanoparticles dissociating at low concentrations found in vivo because 
of its unusually high thermostability (87). This motif is a three way junction (3WJ) that 
serves as the central core structure of the pRNA and connects the helical domain (192)  
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Figure 3.1: Overview of the Phi29 pRNA and the three-way junction (3WJ). (A) i) 
Secondary structure of the Phi29 pRNA monomer with the pRNA-3WJ outlined by the 
box which connects the helical domain to the interlocking procapsid binding domains. ii) 
Secondary structure and sequence of the pRNA-3WJ and the iii) crystal structure of the 
pRNA-3WJ. (B) Assembly gel of the pRNA-3WJ from the three short RNA oligo strand 
on 12% Native PAGE. The 3WJ (lane 7) shows efficiency of folding and particle 
homogeneity before purification. 
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with the two interlocking looped regions of the pRNA (193). It has been determined that 
the 3WJ serves as the central folding domain and provides the overall high stability seen 
in pRNA (87,122). The motif can be formed from three individual RNA oligos at a high 
yield even in the absence of metal ions (87). The novelty behind this structure is in the 
ease of formation and the produced melting curve with a remarkably low Gibbs free 
energy (ΔG) of -28 kcal/mol and a high melting temperature (Tm) of 59.3 °C (223). 
Furthermore it has been proven that the pRNA 3WJ allows the inclusion of RNA 
functional moieties such as receptor-binding aptamer, siRNA, ribozyme, miRNA or 
riboswitch, resulting in the production of functional nanoparticles (87,137,139). The 
addition of functional groups did not interfere with the proper folding of the 3WJ or the 
added functional moieties (87). Previously, attempts have been made to elucidate the 
mechanism for the kinetic stability of the pRNA-3WJ, yet the 3WJ was found to be too 
stable to detect its dissociation by the current technology of radioactive chasing (87). 
The understanding of the mechanism of assembly of the pRNA-3WJ and the 
interaction of the RNA strands is of fundamental importance, but the study of three 
component collisions have not been well-studied in chemistry, biology, or material 
sciences. Here, we investigated the kinetic properties of the pRNA-3WJ using Surface 
Plasmon Resonance (SPR) to study its association and disassociation using bottom-up 
construction RNA nanotechniques. We provided real-time examination of three 
component collision of the pRNA-3WJ. Through these studies, the pRNA-3WJ proves to 
be ultra-stable and only disassociate at extremely low concentration that are atypical to 
other well-studied double-stranded RNA or dimeric macromolecules. Furthermore, the 
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pRNA central motif relies heavily on each of the three strands for rapid folding and slow 
dissociation rates. 
MATERIALS AND METHODS: 
Oligonucleotides and Assembly of 3WJs 
 The pRNA-3WJ was constructed from three RNA oligo fragments. RNA strands 
were produced by Integrated DNA Technologies (IDT). Assembly of the pRNA-3WJ was 
completed by mixing each of the three RNA strands (3WJa, 3WJb, 3WJc) at equal molar 
concentrations at room temperature in TMS buffer (50 mM Tris pH = 8.0, 100 mM NaCl, 
10 mM MgCl2). Samples were then ran on a 12% native polyacrylamide gel at 100 V for 
2 hrs at 4 °C in TBM running buffer (89 mM Tris, 200 mM Borate acid, and 5 mM 
MgCl2) to ensure pRNA-3WJ  proper size folding. 
Surface Plasmon Resonance (SPR) Studies of the pRNA 3WJ 
 The BioRad ProteOn XPR36 was used to complete real time interaction studies 
of the pRNA-3WJ motif. A neutravidin coated HLC chip (BioRad) was used to 
immobilize one of the three 3WJ strands with a 5’ biotin labeled strand of the 3WJ. 
Several studies were completed by immobilizing the 3WJa and 3WJc strand to the chip 
surface, followed by injection and interaction of the remaining two 3WJ strands. All 
studies were conducted at room temperature and in TMS buffer (50 mM Tris pH = 8.0, 
100 mM NaCl, 10 mM MgCl2) with added 0.1% Tween. RNA strands were injected at a 
concentration ranging from 20.0 μM to 78.0 nM at a constant flow rate of 25 μL/min for 
a total of 660 sec, making the analyte RNAs in high excess as an association phase 
followed by injection of blank TMS buffer for 2700 sec at 25 μL/min as a dissociation 
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phase. Real time association and disassociation was observed and displayed into a 
histograph of total response (relationship on mass on chip surface) and time.  
SPR studies of the pRNA 3WJ dimers 
 Utilizing a similar approach as the pRNA-3WJ, the formation and dissociation of 
dimers from the pRNA-3WJ were analyzed. In order to remain consistent in the studies, 
the same concentration gradients were used to examine the formation of two of the three 
strands coming together within the three way junction.  
Kinetic modeling of Surface Plasmon Data 
 Data were extracted from the BioRad ProteOn XPR36 and modeled using Igor 
Pro 6.37. The association periods of the SPR plots were modeled using a Langmuir 
pseudo first-order model consisting of two and three components using the equation 3.1 
and 3.2, respectively. The dissociation of all RNA motifs were modeled using a 
Langmuir zero-order reaction as shown in equation 3.3. 
1      (3.1) 
1      (3.2) 
      (3.3) 
Where R is the response of the SPR in terms of t, time in sec. These kinetic models are derived in 
Appendix 1. In fitting the data, the global fitting package was used in linking the association and 
dissociation of each sample through the kd and Rmax and Ro. 
Calculation of time constant (τ) for complex assembly of pRNA-3WJa, 3WJb, and 3WJc 
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 The time constant (τ) of the pRNA-3WJ core strand was studied through 
Electrophoresis Mobility Shift Assays (EMSA). Single strand of the pRNA-3WJ 
fragments was radio labeled using 5′-end using γ-32P ATP (Perkin Elmer), denoted with 
an asterisk, as previously described (223). The radio labeled oligo was then held at a 
constant concentration of 10 nM and incubated over varying time points ranging from 0 – 
720 min with completed pRNA-3WJ structure at 100 nM concentrations. Samples were 
snap frozen on dry ice and then ran in a 12% polyacrylamide native gel at 100 V for 2 hr 
at 4 °C in TBM running buffer. The gel was then imaged by transferring the radio signal 
to a phosphor screen for 12 hr at -80 °C and visualized using a Typhoon 7000 (GE). Band 
quantification was completed using OriginPro 8.5. The ratio of single strand to 3WJ was 
then calculated and plotted against time. The curve was fitted using equation 3.4 below: 
3 3 ∙       (3.4) 
Where t is the time in seconds and τ is the time constant at which 50% of the labeled 3WJ 
strand was in single strand state and 50% had replaced unlabeled strand in the 3WJ 
complex (196). 
RESULTS AND DISCUSSION: 
Determination of Kinetic Parameters of the pRNA-3WJ 
The BioRad ProteOn XPR36 allows for real time monitoring and analysis of 
molecule association and disassociations. Through the real time analysis, we are able to 
calculate the disassociation constant (defined as KD) by measuring the rates of the 
chemical reactions moving toward the completed 3WJ and the disassociation to single 
RNA strands. 
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Through classic definitions of kinetics, all chemical reactions are viewed to reach 
equilibrium where there is a balance in the production of products and reactants. In the 
case of the pRNA three way junction, a single step chemical reaction is described as the 
equation below: 
3 3 3 →← 3       (3.5) 
and the rate of reaction forming pRNA-3WJ can be written as: 
3 3 3 3     (3.6) 
Where ka is the rate constant of the reaction moving toward the formation of the pRNA-
3WJ and the kd is the rate constant of the reaction moving toward the reactants or 
individual strands of RNA expressed as M-2s-1 and s-1, respectively. At equilibrium these 
rates of reactions forward and backward are equal to each other, creating a balance 
between the formation of the pRNA-3WJ and single stranded RNA. Together the two rate 
constants can be combined to define the disassociation and association constant. 
 and         (3.7) 
Based on previous experiments it was believed that the pRNA-3WJ was 
undergoing a single association and dissociation step following what is seen in equation 
3.5 (87,223). Using SPR, association and disassociation of the pRNA-3WJ was examined 
by binding the 3WJa strand to the chip surface acting as the ligand followed by co-
injecting 3WJb and 3WJc strands acting as analytes. A single transition is seen in the 
association over a range of concentrations from 20 μM to 78 nM. As a result the data was 
fit with a Langmuir three component pseudo-first order model, solving for the reaction 
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rate constants (Fig. 3.2A-B). In these experiments a relatively constant dissociation 
averaging to 4.52x10-05 s-1; this value is within what is expected values of biological 
samples. However, it was seen that the association rate of the pRNA-3WJ was seen 
constant across tested concentrations of 20 to 0.078 μM, thus leading to varying ka values. 
This clearly negates first-order chemical reactions and indicates error in the assembly 
kinetic parameters. 
Calculation of KD of the pRNA-3WJ dimers 
In order to confirm RNA/RNA interactions on the SPR chip, dimers of the pRNA-
3WJ were tested and assembled (Fig. 3.3, Table 3.1). In each of the dimer interactions  
(3WJab, 3WJac, and 3WJbc) Proper association and dissociation periods were produced. 
Furthermore, once the data was fit with a pseudo-first order Langmuir model, it was seen 
that each of the produced kas and kds produced were constant and concentration 
independent. This means the pRNA-3WJ dimers were forming properly on the chip 
surface. Interestingly, in comparing the association rate constants of each of the dimer 
species, the 3WJbc dimer produced the most rapid on rate with a ka of ~1.35x1005 M-1s-1, 
this is nearly an order of magnitude higher than either the 3WJab or 3WJac dimers. 
Furthermore, one would predict the 3WJab dimer to produce the most rapid association 
rate as the dimer helix consists of 9 base pairs compared to the 8 base pairs seen in the 
3WJbc dimer (Fig. 3.1A). In comparing the dissociation rate constants (kd) of the dimers, 
the 3WJab dimer is seen to be the most stable (~6.78x10-05 s-1) followed by 3WJac with a 
kd of ~6.33x10-04 s-1 and finally the weakest dimer being the 3WJbc (~3.95x10-03 s-1). This 
indicates the 3WJbc dimer not only would form the quickest by also dissociate the most 
rapidly. 
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Figure 3.2: Surface Plasmon Resonance (SPR) of the pRNA-3WJ. A) Assembly of 
the 3WJ of three component strands. 5’-Biotin labeled 3WJa was first immobilized to the 
SPR chip surface. 3WJb and 3WJc strands were mixed at equal, varying concentrations, 
ranging from 20 μM to 78 nM, and injected across the chip surface for 330 sec 
(association phase). Following the interaction of the 3WJ strands, blank TMS buffer was 
injected across the chip surface for 2700 sec (dissociation phase). The association and 
dissociation curves were fit using a A) three-component pseudo-first order model. B) 
Calculated Kinetic parameters from SPR curve following a three component pseudo-first 
order kinetic model. C) SPR assay for pRNA-3WJ under assumption of previous dimer 
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formation data. 5’-Biotin labeled 3WJa was first bound to the SPR chip surface. 3WJb and 
3WJc strands were mixed at equal, varying concentrations, ranging from 20 μM to 78 
nM, were injected across the chip surface for 660 sec followed by blank TMS buffer for 
2700 sec. Association and dissociation curves were fit using a two component pseudo-
first order model. D) Kinetic parameters from SPR curves following a two-component 
pseudo-first order kinetic model. 
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Figure 3.3: SPR assay for pRNA-3WJ dimers. Dimer species that make up the pRNA-
3WJ were examined through SPR at varying concentrations ranging from 20 μM to 78 
nM. The injected RNA strand was injected for 660 sec (association phase) followed by 
blank TMS buffer for 2700 sec (dissociation phase). The histographs were then fit using a 
two-component pseudo-first order Langmuir model for A) bound 5’-Biotin 3WJb and 
3WJa, B) bound 5’-Biotin 3WJb and 3WJc, C) bound 5’-Biotin 3WJc and 3WJa. 
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Table 3.1: Kinetic parameters of pRNA-3WJ dimer species 
Ligand Analyte 
ka 
ka Error 
kd 
kd Error 
KD KA 
(M-1s-1) (s-1) (M) (M-1) 
3WJb 3WJa 4.18E+04 2.55E+02 6.78E-05 2.71E-07 2.30E-09 6.73E+08
3WJc 3WJa 3.59E+04 1.37E+03 6.34E-04 8.86E-06 2.71E-08 6.17E+07
3WJb 3WJc 1.37E+05 6.31E+03 3.95E-03 1.95E-05 2.88E-08 3.49E+07
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Next in hopes of gaining insight in the assembly mechanism of the pRNA-3WJ, 
the association rates of the dimer species were compared to the association rate of the 
tested three component one step reaction of the pRNA-3WJ. This was completed by 
calculating association rates (ka’) by taking the fitted rate constants and multiplying by 
the concentration of the studied interaction resulting in an s-1 unit (Table 3.2). It is 
important to note that the pRNA-3WJ was multiplied by a concentration squared value 
while dimers only by concentration due to the difference in units of the kas. Surprisingly, 
it is seen that the pRNA-3WJ produces a rates of reaction on average an order of 
magnitude below the 3WJbc dimer. This would indicate the formation of the dimer 
species is occurring before the formation of the pRNA-3WJ, thus creating an 
intermediate step that was previously not seen through thermodynamic studies (223). 
Determination of time constants of each pRNA-3WJ strand 
 To further gain insight on the formation of a dimer species and the unusual 
formation of the shorter 8 base helix between the 3WJb and 3WJc strands, kinetic studies 
were completed on each of the individual pRNA-3WJ strands. Using a time based strand 
replacement EMSA, time constants were calculated for each of the RNA strands in order 
to examine which, if any of the strands, provides the stability to the 3WJ core. The results 
show that the 3WJa and 3WJb strands produce a similar τ of 38.89 min and 35.93 min, 
respectively, while the 3WJc showed a τ of only 11.81 min (Fig. 3.4). The longer times 
for 50% strand replacement of the 3WJa and 3WJb strands suggests that the structure and 
property of 3WJc strand is special and unique. Using Ethidium bromide or SYBR Green 
staining within gels, the 3WJc is undetectable while both 3WJa and 3WJb are detected 
(87). From these studies, it was determined the 3WJa and 3WJb strands were essential for  
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Table 3.2: Association and dissociation rates of pRNA-3WJ and its components 
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Figure 3.4: Time Constants of 3WJ strands by Electrophoretic Mobility Shift Assays 
(EMSA). The half-life of each 3WJ strand in the pRNA-3WJ were calculated by EMSA 
using 32P labeled free strands, replacing unlabeled strands on assembled pRNA-3WJ. The 
transition of monomer to 3WJ was then plotted and the data was fitted to calculate τ. A) 
3WJa, B) 3WJb, C) 3WJc. 
  
58 
 
the strong stability of the pRNA-3WJ motif; however, the high reactivity of the 3WJc 
strand allows for the rapid association seen in the SPR studies and previous 
thermodynamic studies. 
Association mechanism of the pRNA-3WJ 
  Previous studies on the pRNA-3WJ showed that the three RNA fragments 
associated very rapidly and the formation of a dimer intermediate was undetected. While 
the idea of a one-step association between the three strands seemed highly unlikely it was 
believed that the pRNA-3WJ was formed through the initiation by the folding of a dimer 
with a very rapid addition of the third RNA strand. Here we have found that in fact the 
3WJb and 3WJc strands form a dimer species at a rapid rate, and above what was seen in 
the testing all three strands together. Thus we assume and believe that the two analytes 
(3WJb and 3WJc) were forming into dimer complex and at equilibrium before being able 
to interact with the 3WJa ligand strand on the chip surface. With this idea the pRNA-3WJ 
data was re-analyzed to follow a pseudo-first order reaction that would result in an 
assembly mechanism of 3WJb + 3WJc ↔ 3WJbc + 3WJa ↔ 3WJabc (Fig. 3.2B). Here the 
same dissociation rates were seen as when modeled as a three component system. 
Additionally the rates of association were independent of concentrations tested leading to 
varying rate constant values. The only reasonable explanation for this occurring is the 
real association rate constant is many orders of magnitude below the observed ka and 
working concentrations. This means the rate of the reaction for the 3WJbc + 3WJa ↔ 
3WJabc is occurring so quickly that it cannot be sensed on the SPR due to concentration 
restrictions.  
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Therefore, it is proposed that the pRNA-3WJ undergoes a two-step reaction, in 
which the second reaction takes place immediately following the first at a rate that is too 
fast to currently quantify (Fig. 3.5). This high reaction rate is due to the fact that upon the 
initiation of the 3WJbc formation the affinity for the 3WJa strand increases significantly 
due to the presence of 17 bases for pairing between the two strands, rather than 8 or 9 
base pairs of a single strand. This second high speed reaction is therefore rate limited to 
the first reaction of forming the 3WJbc dimer, thus in examining the formation of the 
pRNA-3WJ a singular step is seen as without the evidence of an intermediate forming. 
Furthermore, each strand and helical region of the pRNA-3WJ plays an important role in 
the rapid formation and high stability. As discussed earlier from the τ values, we know  
the 3WJc strand is highly reactive, this causes results in the highest ka of the 3WJbc dimer. 
While the dimer between the 3WJb and 3WJc strands form the quickest, it also displays 
the shortest dissociation rate showing that the pRNA-3WJ stability is provided through 
other base pairing. The 3WJa and 3WJc strands provide the high stability of the 3WJ as 
shown in their long half-lives and the slow kd seen in SPR studies of the 3WJab. However, 
while the pRNA-3WJ relies heavily on the 3WJab helix region for its stability, the pRNA-
3WJ itself is the most stable motif as shown in having the slowest off rate (kd) (Table 
3.2). This can be attributed to the fact that if one helical region of the pRNA-3WJ breaks, 
the local concentration of the strand is very high compared to what would be seen in 
solution, thus initiating an immediate refolding of that helical region as the second half of 
the strand is still attached to the pRNA-3WJ. As a result of these kinetic studies, the high 
association rate and slow dissociation rate of the pRNA-3WJ results from contributions 
of each of the RNA strands resulting in a three component collision. 
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Figure 3.5: Proposed Assembly Mechanism of the pRNA-3WJ. A) The pRNA-3WJ 
assembles in a two-step mechanism of 3WJb + 3WJc ↔ 3WJbc + 3WJa ↔ 3WJabc, in 
which the first assembly of the 3WJbc dimer is rate limiting. As the dimer is formed it 
immediately folds into the complete pRNA-3WJ due to the increased base pairing 
presented for the 3WJa strand. The second step occurs at an unobservable step, making 
the assembly appear as a B) one-step assembly mechanism. 
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CONCLUSIONS: 
The pRNA-3WJ forms under a two-step assembly mechanism through the 3WJb + 
3WJc ↔ 3WJbc + 3WJa ↔ 3WJabc mechanism, in which the 3WJbc dimer formation occurs 
at a rate constant of ~1x105 M-1s-1 and the formation of the pRNA-3WJ at a rate that was 
unobservable. The resulting motif is more stable than any of its dimers, while each RNA 
strand plays an important role in either the association or dissociation of the 3WJ. The 
pRNA-3WJ show extra-ordinary stability, and ease of formation without an observable 
intermediate, resulting in a stable branched motif that can be used for the construction of 
RNA nanoparticles. 
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INTRODUCTION: 
Functionality of living organisms is made up by a wide variety of molecules 
consisting of DNA, RNA, and proteins. In the past, DNA has been used for its simplistic 
and defined structure in biomaterials (224-227), while proteins have extensively been 
utilized for their diverse structure and functionalities (228). RNA brings together the 
characteristics of the simplicity of DNA and the wide variety of folding structures and 
functions of proteins, making it an attractive candidate for use in nanobiotechnology 
(91,229). Utilizing RNA in therapies provides several advantages over other 
technologies, including: known stoichiometry and defined folding of nanoparticles, 
thereby decreasing the possibility of side effects and toxicity (12,86-88). Multiple RNA 
moieties can be incorporated such as receptor-binding aptamer (32,33), siRNA (97-99), 
ribozyme (92-94), miRNA (100-102), and riboswitch (95,96) through the use of bottom 
up self-assembly (86,97). RNA nanoparticles normally are in the 10-50 nm size range, 
which is the optimal to pass through cell membranes through cell surface receptor 
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mediated endocytosis while still being retained by the body (66-68). Finally, RNA 
nanoparticles can prevent antibody detection by being protein free, but maintain their 
selectivity using receptor-binding aptamers (113-115). The previous problem of 
instability of RNA nanoparticles once hindered the field of RNA nanotechnology (112); 
but 2’-Fluoro (2’-F) modifications to uracil and cytosine backbones not only improves 
the thermodynamic stability but makes the resulting RNA resistant to RNase degradation 
(189,199). With these benefits, a stable RNA nanoparticle would prove to be a beneficial 
therapeutic delivery vehicle that could be used in the specific targeting and treatment of 
cancers and viral diseases. 
Affecting one in every six men and being the second deadliest cancer in men 
(behind lung cancer), prostate cancer is a severe disease that affects a wide population. 
There are roughly 250,000 new cases of prostate cancer diagnosed each year with 30,000 
deaths (American Cancer Society statistics). LNCaP cells are a class of prostate cancer 
cells known for being hormone dependent and androgen sensitive for growth (230-232). 
Extensive work on prostate cancer therapies has previously been done using LNCaP cells 
as they are normally considered a less aggressive cancer (215,233-235). It is beneficial to 
use the early stage cancer cells as a target for therapies, as the tumor has not had time to 
develop into an aggressive state, is still hormonal dependent, and overall easier to 
manage than an hormone independent tumor. This allows for a contained treatment and a 
higher chance of successful removal of the disease. Furthermore, it has been shown that 
LNCaP tumor cells over express Prostate Specific Membrane Antigen (PSMA) (232,236-
238), making it an even more attractive target as it can be easily identified from healthy 
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prostate cells allowing for a specific targeting and delivery of therapeutics while having 
low toxicity effects on normally functioning prostate cells. 
Within cancers, it has been found that many microRNA (miRNA) are either down 
regulated or over-expressed (239-241). The differences in expression from healthy tissues 
have shown adverse downstream effects on many protein expressions, most notably 
leading to down-regulation of tumor suppressors and increased anti-apoptotic genes. 
LNCaP-FGC prostate cancer cells are known to have miR17 and miR21 play important 
roles (242,243), two common miRNAs that have been shown to be directly related to 
cancer progression and growth. These two microRNAs lead to the down-regulation of 
tumor suppressors such as PTEN and PDCD4 and up-regulation of anti-apoptotic genes 
(243-248). The regulation of these important oncogenes could correct the hindered tumor 
suppression and sensitize the cells to apoptosis. Recently anti-miRNA LNA sequences 
have been developed for miR17 and miR21, resulting in the silencing of their respective 
miRNAs (78). However, due to their small size, they display poor biodistribution 
characteristics and are easily cleared from the body. Furthermore, the anti-miRNA 
sequences naturally lack any targeting ability to specifically deliver to cancer cells. 
Previously, a thermodynamically and chemically stable RNA three-way junction 
(3WJ) was discovered within the packaging RNA (pRNA) of the phi29 bacteriophage 
DNA packaging motor (87). pRNA forms into a hexameric ring on the packaging 
connector and consists of two domains, the helical domain and central domain containing 
two interlocking loops) (249-252). The two domains are connected together through a 
3WJ that has been shown to form from three short RNA oligo strands in the absence of 
metal ions (87). The junction also has the ability to harbor RNA moieties off each branch 
65 
 
while still retaining the central folding structure of the 3WJ as well as the functionality of 
the RNA extensions (87). This ultra-stable platform has proven to be a viable scaffold to 
carry RNA functionalities for the use in therapeutics in cancers and viral diseases 
(87,123,137,139). 
Using the pRNA-3WJ, we propose to create a RNA molecule with specific 
targeting ability to prostate cancer cells to carry miRNA LNAs (78). Here we report the 
use of the pRNA-3WJ for the construction of RNA nanoparticles for the specific 
targeting of prostate cancer tumor cells. LNCaP-FGC cells were used as in vitro cell 
model and the over-expression of the PSMA in LNCaP-FGC cells was used as a specific 
target. Targeting was achieved through the use of the PSMA A9g RNA aptamer that has 
been previously developed (253,254), and conjugated onto the pRNA-3WJ through 
bottom-up construction. Furthermore, we have conjugated anti-miRNA LNAs as well as 
fluorescent tags onto the remaining two branches of the three way junction for 
monitoring the binding and entry into the tumor cells. Nanoparticles were successfully 
constructed with defined stoichiometry and size that maintained the folding structures of 
both the pRNA-3WJ and A9g PSMA aptamer, keeping the functionality of the aptamer. 
The molecules further showed specific targeting to LNCaP-FGC cells in vitro through 
flow cytometry, cell confocal microscopy, and dual luciferase assays. Dual luciferase 
assays and qRT-PCR reported specific knockdown of miR21 and miR17 in LNCaP cells. 
Through these studies, we have proven that the combination of the A9g PSMA aptamer 
with anti-miRNA LNAs through the pRNA-3WJ into therapeutic nanoparticles, selective 
targeting to prostate cancer, specifically LNCaP-FGC cells, can be accomplished, 
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providing a vehicle for therapeutical elements like siRNAs, miRNAs, or chemotherapies 
for tumor treatments. 
MATERIALS AND METHODS: 
Design and construction of pRNA-3WJ nanoparticles harboring PSMA binding 
aptamer and anti-miRNA LNA 
 RNA nanoparticles were constructed using a bottom-up approach, as previously 
described. Briefly, DNA oligos primers (Integrated DNA Technologies) were used to 
create dsDNA templates through polymerase chain reaction (PCR) for each RNA strand. 
RNA strands were then transcribed by T7 polymerase in vitro. Additionally 2’-fluoro (2’-
F) modified cytosine and uracil were used in transcriptions along with an Y639F mutant 
T7 polymerase, giving nuclease stability to the RNA strands. The anti-micro RNA LNAs 
were synthesized by Exiqon. 
Transcribed RNA strands were purified on 8% polyacrylamide gels containing 8 
M Urea ran at 120 V for 1.5 hours on TBE running buffer (89 mM Tris-borate, 2 mM 
EDTA). RNA bands of interest were excised from the gel using UV shadow on thin layer 
chromatography plates and eluted from gel in elution buffer (0.5 M Ammonium Acetate, 
0.1 mM EDTA, 0.1% SDS) at 37 °C for a minimum of 3 hours and then precipitated by 
ethanol. 
RNA nanoparticles were assembled by mixing strands at equal molar 
concentrations in TMS buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10 mM MgCl2) and 
heated to 80 °C for 5 minutes and slowly cooled over 40 minutes to 4 °C. Assembled 
RNA nanoparticles were then purified on 8% polyacrylamide gels at 100 V for 2 hours 
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on TBM running buffer (89 mM Tris, 200 mM borate acid, and 5 mM MgCl2) and at 4 
°C. Samples were then excised and eluted as described above. 
Temperature Gradient Gel Electrophoresis (TGGE) assay for studying thermodynamic 
stability of RNA nanoparticles 
 For TGGE analysis, the experimental setup was adjusted to have a linear 
temperature gradient perpendicular to the electric field (BiometraHmbGh). The 
temperature gradient was set from 36.0 °C to 80.0 °C. RNA sample (500 nM) was 
combined with 6× gel loading buffer and run on 8% native PAGE at 100 V for 1 h. 10 
mM MgCl2 was present in both gel and electrophoresis buffer. The nanoparticles 
contained a Cy5 fluorophore on the 3WJb strand for monitoring melting and imaged by 
Typhoon FLA 7000 (GE Healthcare). The pRNA-3WJ constructs within the total RNA 
was analyzed by ImageJ, and the melting curve of the construct was fitted using 
nonlinear Sigmoidal fitting. Melting temperatures (Tm) were calculated where 50% of 
total RNA concentration was at ssRNA and 50% was in complexed 3WJ form. 
Serum stability assay for studying chemical stability of RNA nanoparticles 
400 ng of pRNA-3WJ nanoparticle was incubated in TMS buffer containing fetal 
bovine serum (FBS, final concentration is 10%). The total volume was 10 µl. Samples 
were taken at multiple time points, including 0, 0.25, 0.5, 1, 2, 6, 12, and 24 hours after 
incubation at 37 °C. 8% Native TBM PAGE gel electrophoresis was applied to visualize 
RNA. After running for 1.5 hr at 4 °C, the gel was stained by ethidium bromide. Images 
were taken by Typhoon FLA 7000 (GE Healthcare). 
Dynamic light scattering and Zeta potential measurement of RNA nanoparticles 
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 Apparent hydrodynamic sizes and zeta potential of pre-assembled A9g-3WJ-anti-
miR21 LNA and A9g-3WJ nanoparticles were measured by a Zetasizer nano-ZS 
(Malvern Instrument, LTD). All RNA samples were measures at 2 μM in DEPC H2O and 
PBS buffer (137 mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) at 
25 °C. 
Cell Culture 
Human prostate cancer cell lines LNCaP-FGC, LNCaP C4-2 and PC-3 (American 
Type Culture Collection, ATCC) were grown and cultured in RPMI 1640 medium 
(Invitrogen) containing both 10% fetal bovine serum (FBS) and penicillin/streptomycin 
in a 37 °C incubator with a 5% CO2 and a humidified atmosphere. 
Flow Cytometry assay of PSMA pRNA-3WJ nanoparticles binding to LNCaP-FGC 
cells 
 LNCaP-FGC and PC-3 cells were trypsinized and rinsed with blank RPMI-1640 
medium. 100 nM Cy5 labeled A9g-3WJ and the control pRNA-3WJ were each incubated 
with 2 × 105 LNCaP-FGC or PC-3 cells at 37 °C for 2 hr. After washing with PBS (137 
mM NaCl, 2.7 mM KCl, 100 mM Na2HPO4, 2 mM KH2PO4, pH 7.4), the cells were 
resuspended in PBS buffer. Flow Cytometry was performed by the UK Flow Cytometry 
& Cell Sorting core facility to observe the cell binding efficacy of the Cy-5 A9g-3WJ 
nanoparticles. Analysis was completed using Flowing Software v2.5 (Turku Centre for 
Biotechnology). 
Confocal Microscopy imaging analyzing RNA nanoparticle binding and entry into 
LNCaP-FGC cells 
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LNCaP-FGC and PC-3 cells were grown on glass coverslides in RPMI-1640 
medium overnight. 100 nM concentration Alexa647 labeled A9g-3WJ and the control 
pRNA-3WJ were each incubated with the cells at 37 °C for 2 hr. After washing with 
PBS, the cells were fixed by 4% paraformaldehyde and stained by Alexa Fluor® 488 
phalloidin (Invitrogen) for cytoskeleton and TO-PRO®-3 iodide (642⁄661) (Invitrogen) 
for nucleus. The cells were then assayed for binding and cell entry by Zeiss LSM 510 
laser scanning confocal microscope.  
Dual Luciferase Assay to analyze delivery of anti-miRNA by pRNA-3WJ nanoparticles 
LNCaP-FGC and PC-3 cells were grown on 24-well plates in RPMI-1640 
medium until reaching ~80-90% confluency. 100 nM and 50 nM A9g-3WJ-anti miRNA 
LNA and the control RNAs including pRNA-3WJ/anti-miRNA-(17 or 21) LNA and 
A9g-3WJ were incubated with cells in opti-MEM at 37 °C for 3 hr. As a positive control, 
anti-miRNA LNA transfected by RNAi MAX (following standard protocol by 
Invitrogen) into cells, while complete nanoparticles were merely incubated with cells. 
After incubation with the RNA, cells were washed once with blank RPMI-1640 medium 
and then transfected with psi-Check 2 plasmid (Promega) which contains an oncogenic 
miRNA targeting sequences at the 3’-UTR region of Renilla Luciferase gene using 
Lipofectamine 2000 (Life Technologies). Dual-luciferase assay (Promega) was used to 
evaluate the anti-miRNA LNA effects 24 hr post-transfection upon manufacture’s 
instruction. Briefly, cells were washed once with PBS and lysed with passive lysis buffer. 
The plates were shaken for 30 minutes at room temperature. 20 μL of the lysate were 
added to 50 μL of luciferase assay reagent (LAR II) in a luminometer tube and firefly 
luciferase activity was measured. Upon addition of 50 μL of Stop & Glo Reagent, control 
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measurements of Renilla luciferase activity were then obtained. The Renilla luciferase 
activity obtained was then normalized with respect to the Firefly luciferase activity for 
determining the average ratio of Renilla to Firefly luciferase activity over several trials. 
Results were statistically analyze by an ANOVA two-way test in comparing Renilla 
expression to the cell only control and between PC-3 and LNCaP cell lines among each 
concentration.  
qRT-PCR assay 
Two A9g-pRNA-anti-miRNA LNA constructs were assayed for the subsequent 
gene up-regulation effects: one harboring anti-miR21 LNA; and, the other harboring anti-
miR17 LNA. 
 LNCaP-FGC cells were incubated with 10 and 100 nM of the individual A9g-
3WJ-anti-miRNA LNA and control RNAs as described above. After 72 hr treatment, 
cells were collected and target gene up-regulation effects were assessed by qRT-PCR. 
PC-3 cells were used as negative control cell line. 
 Cells were processed for total RNA using Trizol RNA extraction reagent 
following manufacture’s instruction (Life Technologies). The first cDNA strand was 
synthesized on total RNA (1 μg) from cells with the various RNAs treatment using 
SuperScriptTM III First-Strand Synthesis System (Invitrogen). Real-time PCR was 
performed using Taqman Assay. All reactions were carried out in a final volume of 20 
μL using Taqman Fast Universal PCR Master Mix and assayed in triplicate. 
Primers/probe set for human PTEN and 18S were purchased from Life Technologies. 
PCR was performed on Step-One Plus real time PCR system (Applied Biosystem). The 
data was analyzed by the comparative CT Method (ΔΔCT Method). Data was statistically 
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analyzed by an ANOVA one-way test in comparing values with the cell only control in 
each concentration and gene. 
Caspase III assay for studying cell viability upon pRNA-3WJ nanoparticle treatment 
LNCaP-FGC cells were plated in 24-well plate and incubated with 100 nM A9g-
3WJ-anti miRNA LNA constructs and control RNAs as described above at 37 °C for 24 
hr. A positive control of incubating cells with 5 μM Campothecin for 4 hr at 37 °C was 
used. Caspase III signaling was then assayed using Caspase III Assay Kit (BD 
Pharmigen) following the standard protocol. Cells were washed in 1× PBS buffer 
followed by incubated in 200 μL Cell Lysate Buffer for 30 min on ice. 100 μL of cell 
lysate was then incubated with 1 mL of 1× HEPES Buffer and 15 μl Ac-DEVD-AMC 
fluorescent substrate and incubated at 37 °C for 1 hr. Fluorescence was the measured 
from 420 to 460 nm with an excitation of 380 nm on fluorospectrometer (Horiba Jobin 
Yvon; SPEX Fluolog-3). A peak fluorescence at 440 nm was used to analyze Caspase III 
signaling. 
In vivo biodistribution and tumor targeting of RNA nanoparticles 
 LNCaP C4-2 cells were cultured in vitro and subcutaneously injected under the 
skin of 4 week old male nude mice. A total of 2×106 cells were injected in solution with 
Matrigel (Corning) as a 50/50 % blend. Tumors were grown for 4 weeks until tumors 
reached a volume of 200 mm3. Mice were then administered PBS (blank control), pRNA-
3WJ (negative control), and A9g-3WJ each with Alexa647 labels as naked oligos at a dose 
of 2 μM at 100 μL through the tail vein. Mice were imaged for whole body fluorescence 
at time points 0, 1, 2, 3, 4, and 8 hours with an IVIS imager (Caliper Life Sciences). 
Upon the completion of the study, mice were sacrificed, and tumors, hearts, kidneys, 
72 
 
livers, and brains were collected and imaged by the whole body imager for Alexa647 
signal. Additionally, tumors were frozen at ‒80 °C, and sectioned for confocal 
microscopy as described above. 
 Furthermore, tumors were fixed in 4% paraformaldehyde with 10% sucrose in 1x 
PBS buffer at 4 °C overnight. Tumor samples were then placed in Tissue-Tek O.C.T. 
compound (Sakura Finetek USA, Inc.) for frozen sectioning (10 μm thick). Sectioned 
tissue were then stained with DAPI and mounted with ProLong Gold Anti-fade Reagent 
(Life Technologies) overnight. Slides were then fluorescently imaged by FluoView 
FV1000-Filter Confocal Microscope System (Olympus).  
In vivo tumor reduction by anti-miRNA LNA pRNA-3WJ nanoparticles 
 LNCaP C4-2 cells were grown and subcutaneously injected into 4 week old male 
nude mice. 2×106 cells were injected as a 50% cell, 50% Matrigel (Corning) blend into 
the flank of the mice with a total of 5 mice hosting 2 tumors each. Xenograft tumors were 
monitored until they reached roughly 200 mm3 in volume. Naked RNA nanoparticles 
harboring the PSMA A9g aptamer and anti-miRNA LNAs were injected through the tail 
vein of mice at a concentration of 20 μM at 100 μL on days 7, 10, 13, 17 and 20 while 
monitoring tumor volume and total mouse weight up to day 29. 
Western blot of miRNA downstream genes of xenograft tumors 
Upon the completion of tumor reduction experiments, mice were sacrificed and 
tumors were harvested. LNCaP C4-2 tumors were homogenized in RIPA buffer 
containing Protease (ThermoFisher). Total protein concentration was measured by BCA 
protein assay (ThermoFisher) against protein standards. 100 μg of total protein from the 
tumor was loaded onto TDX FastCast SDS PAGE gels (BioRad) and ran at 100 V for 2 
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hr. Gels were transferred onto membranes and stained with PTEN, PDCD4, and β-Actin 
antibodies (Cell Signaling) and imaged. β-Actin was used as an internal control and 
PTEN and PDCD4 are expressed as a ratio with β-Actin. 
RESULTS AND DISCUSSION 
Construction of pRNA-3WJ nanoparticles harboring PSMA binding aptamer 
An RNA aptamer using 2’-Fluoro modified nucleotides was generated through 
SELEX (Systematic evolution of ligands by exponential enrichment) for specific 
targeting of PSMA by Lupold et al (253). Furthermore, Rockey et al. rationally truncated 
the A9 PSMA aptamer shortening the overall length while keeping the high specificity to 
PSMA (254). It is well known that prostate specific membrane antigen is overexpressed 
in LNCaP-FGC prostate cancer cells (231,232,255-258). PSMA is an important target 
since it is overexpressed in primary prostate tumors as well as metastases in the lymph 
nodes (259). Furthermore, PSMA has been shown to be upregulated in tumors after 
patients have been treated with common androgen-deprivation therapies (257,260). The 
truncated PSMA A9g aptamer was placed onto the pRNA-3WJ, creating a branched 
RNA motif to specifically target prostate cancer cells. RNA 3WJs were created with the 
PSMA aptamer attached to the 3WJa/3WJc branch in three different orientations (Figs. 
4.1, 4.3) in order to test if there is any variation in the aptamer folding once placed on the 
pRNA-3WJ. Each of the three variants of the A9g-3WJ displayed proper folding and 
sizing on polyacrylamide gels ran in native conditions. 
Next the prostate targeting 3WJs were tested for nuclease and thermodynamic 
stability. First each of the 2’-F modified A9g-3WJs were incubated with 10% fetal bovine 
serum over 24 hours (Fig. 4.2A). Samples were then ran on polyacrylamide gels, where  
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Figure 4.1. Design and construction of pRNA-3WJ nanoparticles harboring PSMA 
binding aptamer and anti-miRNA LNA. A) The sequence and secondary structure of 
bacteriophage phi29 packaging RNA (pRNA). B) 3WJ core of pRNA. C) Design of 
pRNA-3WJ nanoparticles harboring PSMA binding aptamer and anti-miRNA LNA. D) 
10% native TBM PAGE of A9g-3WJ-anti-miR21 nanoparticle. 
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 Figure 4.2. The stability and characterization of assembled pRNA-3WJ 
nanoparticles harboring PSMA binding aptamer and anti-miRNA LNA. A) 
Assessment of chemical stability of A9g-3WJ-anti-miRNA LNA treated with 10% serum 
contained cell culture medium in 8% TBM native PAGE. B) Assessment of 
thermodynamic stability of A9g-3WJ-anti-miRNA LNA by TGGE assay. Melting profile 
of nanoparticle derived from PAGE with sigmoidal fitting of data to find melting 
temperature. C) Hydrodynamic sizing and zeta potential measurements of the A9g-3WJ-
anti-miR21 nanoparticle using a Zetasizer nano-ZS. 
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Figure 4.3. Flow Cytometry assay for studying specific binding of pRNA-3WJ 
nanoparticles on prostate cancer cells. A) Illustration of various design of conjugating 
PSMA binding A9g aptamer onto the pRNA-3WJ core. Alexa647 labelled A9g-3WJ RNA 
nanoparticles were incubated with B) PSMA+ LNCaP-FGC cells and C) PSMA- PC-3 
cells. Nanoparticles indicated positive binding of nanoparticles to LNCaP cells while 
avoiding non-specific binding to PC-3 cells.  
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the band corresponding to the assembled RNA nanoparticles remained stable throughout 
all time points. This data shows the RNA nanoparticles will remain stable during in vivo 
applications as RNases are not able to recognize and degrade the fluoro modified nucleic 
acids. Furthermore, the thermodynamic stability of the PSMA targeting 3WJ was assayed 
using temperature gradient gel electrophoresis. Temperature gradient was applied 
perpendicular to the electrical current in order to find the melting temperature of the 3WJ 
harboring the aptamer (Fig. 4.2B). Previously the melting temperature (Tm) of 2’-F 
modified pRNA-3WJ core was found to be 69.8 °C (223). From the TGGE melting 
curve, the melting temperature of the A9g-3WJ was found to be 61.2 °C. Although the 
Tm of the aptamer-3WJ complex is less than the 3WJ itself, the still rather high melting 
temperature of the nanoparticle indicates the PSMA A9 aptamer does not significantly 
hinder the stability of the pRNA-3WJ core, and in fact the 3WJ actually provides added 
stability to the PSMA aptamer.  
After establishing that A9g-3WJ displayed the high stability previously seen in 
the pRNA-3WJ, the targeting 3WJ was expanded to harbor anti-miRNA LNAs for testing 
the delivery of therapeutics to LNCaP-FGC cells (Fig. 4.1C). The extended helical 
regions off of the unoccupied branch of the 3WJ posed no problem in folding of the RNA 
strands, as all completed nanoparticles were assayed on polyacrylamide gels ran in native 
conditions (Fig. 4.1D). Assembly gels showed high yield of the folded RNA 
nanoparticle, without any side product bands being contributed to mismatch in RNA 
concentrations during assembly. Within the assembly gel, two bands were seen from the 
A9g-3WJ strand and the A9g-3WJ-anti-miRNA samples, this was attributed to formation 
of a self-dimer of the A9g aptamer. Furthermore assembled nanoparticles, A9g-3WJ and 
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A9g-3WJ-anti-miR21 LNA, were tested for zeta potential and hydrodynamic size (Fig. 
4.2C). Here it was found that the size of the nanoparticles were 3.77 ± 0.59 nm and 4.27 
± 0.32 nm, with a zeta potential of -18.0 ± 1.45 mV and -22.87 ± 2.40 mV, respectively. 
These values are in line with predictions and previously published results of other RNA 
nanoparticles (83,125,126). 
Targeting of pRNA-3WJ nanoparticles to LNCaP-FGC cells 
In order to test the targeting of the pRNA-3WJ, either a fluorescent Alexa647 or 
whole chain labeling with Cy5 fluorophore was placed on the 3WJb strand to allow for 
tracking of the RNA nanoparticles created and described above. The A9g-3WJ 
nanoparticles were incubated with LNCaP-FGC cells, as well as PC-3 cells (PSMA‒) as a 
negative control. Following the RNA incubation and washing steps cells were analyzed 
by flow cytometry to confirm the binding of each of the three A9g-3WJs. FACS data 
showed each of the designs showed strong binding (>75%) to LNCaP-FGC cells while 
the aptamer negative pRNA-3WJ displayed only 6.59% binding (Fig. 4.3). However, 
with this high binding it was found that the two designs with hinging aptamers produced 
an increased and undesired non-specific binding to PC-3 cells. Therefore connecting the 
A9g PSMA aptamer to the pRNA-3WJ directly to the two helical regions of the 
3WJa/3WJc branch provided the highest binding to LNCaP-FGC (91.22 %), while having 
low non-specific binding to PSMA- PC-3 cell line (11.60 %) (Table 4.1). Flow 
cytometry data displayed that the addition of the pRNA-3WJ to the end of the PSMA 
A9g aptamer did not interrupt cell binding, and provided a branched scaffold for the 
addition of therapeutic elements such as siRNAs, miRNAs, and anti-miRNAs. 
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Table 4.1. Summary of flow cytometery binding data 
Sample (100nM) LNCaP PC-3 
3WJ (negative) 6.6% 4.4% 
A9-3WJ version 1 91.2% 11.6% 
A9-3WJ version 2 77.8% 26.6% 
A9-3WJ version 3 82.6% 21.6% 
Aptamer (positive) 87.6% 9.2% 
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Next, endocytosis entry of the RNA nanoparticles harboring the PSMA A9g 
aptamer into LNCaP-FGC cells was examined. In order for proper delivery of 
therapeutics and RNA nanoparticles to act as anti-cancer agents, entry into the cells are 
required for proper release of therapeutic agents. Alexa647 labeled A9g-3WJ nanoparticles 
were incubated with LNCaP-FGC and PC-3 cells, cells were then fixed and the nuclei 
and cytoplasm were stained. Confocal microscopy images shows proper binding of the 
A9g aptamer to LNCaP cells with very little signal seen on PC-3 cells. Furthermore, 
confocal imaging along with Z-axis stacking imaging (Fig. 4.4) confirmed Alexa647 signal 
within LNCaP-FGC cells on A9g positive nanoparticles. Additionally, little Alexa647 
signal was seen around cells samples without the PSMA aptamer and the signal was only 
seen accumulating around the LNCaP cells and not within. This data displays that PSMA 
A9g aptamer is not only specifically binding to PSMA+ cells, but entering through  
receptor mediated endocytosis as expected. Additionally, cell binding assays were 
completed using VCaP (PSMA+) and Jurkat (PSMA-) cell lines to further test the 
specificity of the A9g-3WJ nanoparticles (data not shown). Here very similar binding 
profiles were seen as with LNCaP and PC-3 cells further confirming the targeting of the 
A9g aptamer. With positive detection of nanoparticles in the LNCaP-FGC cells, it is 
possible to deliver therapeutics in hopes of leading to apoptosis of LNCaP cells through 
RNA interference (RNAi). 
Delivery of anti-miRNA LNA to LNCaP-FGC cells 
Upon confirmation of PSMA targeting nanoparticles entering into LNCaP-FGC 
cells, experiments were expanded to test the delivery of therapeutic components. LNCaP-
FGC cells are known to overexpress miR17 and express miR21, two common oncomirs  
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Figure 4.4. Confocal Microscopy for assaying the binding and internalization of 
pRNA-3WJ nanoparticles via PSMA binding aptamer A9g. RNA nanoparticles were 
incubated with cell groups then fixed and stained for fluorescent imaging. A) A9g-3WJ to 
LNCaP cells. B) A9g-3WJ to PC-3 cells. C) 3WJ control to LNCaP cells. D) A9g 
aptamer control to LNCaP cells. Blue: DAPI stained nucleus. Green: Phalloidin-Alexa 
488 stained cytoplasm. Red: Alexa 647 labeled RNA nanoparticles. Overlay of 3 signals 
with z-axis scanning.  
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that are seen in cancers (242,243). These two microRNAs lead to the down-regulation of 
tumor suppressors such as PTEN and PDCD4 and up-regulation of anti-apoptotic genes 
(243-248). Additionally miR-21 has been shown to promote hormone independency 
prostate cancers (261) and enhances the invasiveness of LNCaP cells (262); while miR17 
has been proven to promote tumor growth and invasiveness in prostate cancer cells (263). 
Therefore, silencing miR17 and miR21 could lead to the sensitization of the LNCaP-FGC 
cells leading to apoptosis. Anti-miRNA sequences have been developed to target, and 
bind miR17 and miR21, thus blocking their gene silencing roles (78). 
These anti-miRNAs were placed onto the PSMA A9g-3WJ by a DNA linker 
strand for delivery into LNCaP-FGC cells (83). Incubation studies of the RNA 
nanoparticles harboring the PSMA RNA aptamer with the miR17 and miR21 were 
completed testing the delivery using Promega’s psi-check2 dual luciferase plasmid. The 
transfected plasmid contained sequences for Firefly and Renilla luciferase plasmids with 
each plasmid containing the microRNA targeting sequences at the 3’-UTR region of 
Renilla luciferase, respectively. Therefore in the native cells, the Renilla expression 
would be knocked-out, as the miRNA would bind to plasmid, preventing the translation 
of Renilla luciferase proteins, but Firefly expression would remain unaffected. As anti-
miRNA LNA sequences are delivered to the cells, miR17 and miR21 are knocked-down, 
thus resulting in an increased expression of Renilla in the dual luciferase assay. 
By incubating RNA nanoparticles with LNCaP and PC-3 cells, miR17 and miR21 
knock-down was assayed by the described dual luciferase assay. Data in LNCaP-FGC 
cells shows significant increase in Renilla expression in the A9g-3WJ-anti-miRNA LNA 
and anti-miRNA LNA transfected samples; however, little effect seen from PSMA 
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aptamer negative samples for both miR17 and miR21 (Fig. 4.5A-B). This shows the anti-
miRNA sequences are being properly delivered to LNCaP-FGC cells by the PSMA A9g 
aptamer and processed by RISC. Additionally, studies completed in PC-3 cells showed 
significantly less increase in Renilla expression from the A9g-3WJ-anti-miRNA LNA 
samples, indicating RNA nanoparticles were selectively targeting LNCaP cells through 
PSMA binding, indicating a low toxicity to PSMA- cell lines. Furthermore, due to the 
fact that the aptamer sequence is on a different strand from the anti-miRNA sequences, 
these studies indicate that the RNA nanoparticles are remaining stable and intact through 
the pRNA-3WJ core throughout the studies. 
To further confirm the delivery of anti-miRNA LNA sequences into LNCaP-FGC 
cells and the ability for the LNAs to effect downstream gene expressions quantitative real 
time PCR was completed, examining the expression of PTEN and PDCD4, known 
downstream genes of both miR17 and miR21. 18S was used as an internal control during 
these experiments to standardize the expressions of PTEN and PDCD4 mRNA. q-rtPCR 
results show significant increase of PTEN at only a 10 nM concentration of RNA 
nanoparticles in the A9g-3WJ-anti-miR21 samples over the negative controls (Fig. 4.5C). 
Additionally it was seen that the RNA nanoparticles were able to slightly increase the 
PDCD4 expression slightly over negative controls and the cell only samples. These data 
further prove the delivery of anti-miRNA LNAs to LNCaP-FGC cells through the A9g-
3WJ complex. Furthermore, the increase of tumor suppressor genes not only shows a true 
knockdown of the miRNAs, but displays the RNA nanoparticles’ ability to correct errors 
in gene expressions caused by the prostate cancer. 
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 Figure 4.5. Assay for miRNA knockdown and downstream gene regulation effects 
of pRNA-3WJ nanoparticles harboring PSMA binding aptamer and anti-oncogenic 
miRNA LNA. A) Dual-luciferase assay for evaluating delivered anti-miR21 LNA and B) 
anti-miR17 LNA effects on prostate cancer cells from incubation of RNA nanoparticles. 
Knockdown of miRNAs led to spiked increase of reporter Renilla expression. C) qPCR 
results of downstream genes PTEN and PDCD4 expression as a result of miR21 
knockdown in LNCaP cells 72 hours post incubation with A9-3WJ-anti-miR21 LNA 
nanoparticles. D) Design of A9g-3WJ-anti miR21 LNA and -anti-miR17 LNA 
nanoparticles. In all plots *p<0.1, **p<0.01, ***p<0.001.  
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From the confirmed up-regulation of tumor suppressor genes by delivery of 
miRNA LNAs by the 3WJ, testing of apoptotic effects were completed through assaying 
Caspase III signaling on LNCaP-FGC and PC-3 cells after incubation with A9g-3WJ-
anti-miRNAs along with negative nanoparticle controls described before (Fig. 4.6). The 
PC-3 cells and negative RNA nanoparticles with LNCaP cells were used to show the 
RNA nanoparticles were not toxic to the cells and apoptosis only occurred through 
specific delivery of the anti-miRNA LNAs. A spike in Caspase III signaling was seen in 
LNCaP cells treated with A9g-3WJ-anti-miR17 and transfected by RNAi Max anti-
miRNA LNAs (Fig. 4.6). This indicates that the silencing of miRNA was able to 
successfully lead to the death of LNCaP cells. Here apoptosis caused by the decreased 
expression of miR17 shows the important role of the miRNA in LNCaP cells and the 
ability to control the cell growth and death through its expressions. 
Through this data, the prostate cancer targeting RNA nanoparticles delivering the 
anti-miRNA LNAs shows the vast possibility of RNA nanoparticles. Here, we show 
constructed nanoparticles using the pRNA-3WJ were stable in FBS, being resistant to 
RNases and stable at temperatures well above the 37 °C needed for in vivo applications. 
Furthermore, the 3WJ harboring the PSMA aptamer and anti-miRNA LNAs and positive 
functionality of each shows the versatility of the pRNA-3WJ to harbor RNA moieties 
while keeping the original functionality of each of the RNA groups; i.e. the targeting and 
binding of the PSMA aptamer and the silencing ability of the anti-miRNA LNAs. 
Through these experiments, we have shown that stable RNA nanoparticles can be 
constructed for the specific targeting and treatment of cancers, and past hurdles that have 
held back the field of RNA nanotechnology are no longer a concern. 
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 Figure 4.6. Caspase III signaling assay for apoptosis effects of 3WJ-pRNA 
nanoparticles harboring PSMA binding aptamer and anti-oncogenic miRNA LNA. 
RNA nanoparticles with anti-miR21 and -miR17 LNA were incubated with A) LNCaP 
and B) PC-3 cells cells for 24 hours. Caspase III signaling was assayed by fluorescent 
reporter with peak fluorescent of 440 nm as a reporter of cell apoptosis as a result of 
RNA nanoparticle delivery of anti-miRNA sequences. 5 μM Campothecin was used as a 
positive control and benchmark of apoptosis (**p<0.01, ***p<0.001). 
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In vivo delivery of anti-miRNA LNA to LNCaP 
Subcutaneous xenograft tumors were developed in male nude mice with LNCaP 
C4-2 cells. Once tumors were fully developed (2 weeks) with cardio vasculature, 100 μL 
of 20 μM solution of pRNA-3WJ nanoparticle harboring the PSMA A9g aptamer along 
with an Alexa647 fluorescent tag were administered to the mice through tail-vein 
injection. For all in vivo studies, nanoparticles were injected and delivered as bare oligos 
without the aid of any additives. Through a series of time points, mice were whole body 
imaged to examine the biodistribution of nanoparticles, along with the accumulation in 
tumors as well as healthy organs. Initially Alexa647 was detected throughout the whole 
body of the mice indicating nanoparticles successfully circulated through the mice. 
Through early time points, Alexa647 concentrated in the tumor, liver, and bladder of the 
mice; indicating the excess nanoparticles were excreted through the urine. After 8 hours, 
fluorescence signal was undetectable in all healthy organs was remaining strong in the 
xenograft tumor (Fig. 4.7A). Additionally tumors were sectioned and imaged for 
fluorescent imaging (Fig. 4.7C). Confocal imaging shows specific targeting and 
accumulation of the A9g-3WJ nanoparticles to the LNCaP xenograft tumor. This 
indicates nanoparticles have no lasting accumulation in the liver or kidneys, thus having 
low toxicity profiles. 
Furthermore the therapeutic effects of the A9g-3WJ-anti-miRNA nanoparticles 
were tested in vivo on LNCaP C4-2 subcutaneous xenografts. After tumors were 
developed to a volume of ~200 mm3, nanoparticles harboring the anti-miR17 and –
miR21 LNAs were administered to the mice through a series of five tail vein injections. 
Tumor volume and total weight of the mice were monitored throughout this experiment.  
88 
 
 
Figure 4.7. In vivo delivery of 3WJ-pRNA nanoparticles harboring PSMA binding 
aptamer and anti-miRNA LNA. RNA nanoparticles were delivered as bare oligos to 
LNCaP C4-2 subcutaneous xenografts in nude mice. A) Biodistribution of A9g-3WJ-
Alexa647 through nude mice. B: Brain, L: Lung, S: Spleen, Lv: Liver, K: Kidney, T: 
Tumor. B) Tumor bearing nude mice were administered nanoparticles through a series of 
five injections through the tail vein of 20 μM solution at 100 μL (indicated by arrows), 
while tumor volume (mm3) and total mouse weight (g) were monitored (*P<0.05, 
**P<0.01, ***P<0.0001). C) Fluorescent confocal microscopy of tumor samples 8 hr 
post i.v. administration of RNA nanoparticles. DAPI (Blue) is cell nucleus, Alexa647 (red) 
is RNA nanoparticle. D) Western blot examining downstream expression of PTEN and 
PDCD4 from silencing of miR17 and miR21 using β-Actin as an internal control.
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From the tumor volume data (Fig. 4.7B), it can clearly be seen that the A9-3WJ-anti-
miRNA samples led to a stunted tumor growth and proliferation compared to negative 
controls, thus indicating the anti-miRNA oligos had a profound effect on the tumor 
environment and cell growth. Even after post-administration of the nanoparticles, a lack 
of growth in the tumors was seen for several days compared to non-treated tumors. 
Furthermore, there was no significant change in the mice weights over the observed RNA 
nanoparticle delivery indicating no toxicity in the mice and the tumor reduction was as a 
result of specific delivery to the tumors. 
At the conclusion of in vivo delivery of the pRNA-3WJ nanoparticles, mice were 
sacrificed and tumors were harvested. PTEN and PDCD4 expressions were measured in 
the tumors, using β-Actin as an internal control. Western blots (Fig. 4.7D) show an 
increase in PTEN and PDCD4 in the pRNA-3WJ nanoparticles harboring the anti-
miRNA LNAs. These results display the same ability of the 3WJ-pRNA nanoparticles as 
seen in vitro with the LNCaP cells, as the anti-miRNA sequences led to the increase of 
expression tumor suppressor genes as a result of decreased miR21 and miR17 
expressions. On average an increase was seen in the A9g-3WJ sample over the control 
but less than A9g-3WJ-anti-miRNA groups. This may have been due to the repeated 
dosage of the RNA to the tumor cell in the animal trials, the larger volume of the 
nanoparticle may have had an effect on the gene expression within the tumor; however, 
the change in gene expression was not enough to create a change in tumor growth as 
shown in Fig. 4.7B. Here we demonstrate not only the ability of the RNA nanoparticles 
to accumulate and target the tumor specifically with high affinity, but deliver anti-
oncogenic RNA sequences to regulate tumor growth and development of tumors. 
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CONCLUSIONS 
Here we created RNA nanoparticles using the pRNA-3WJ core from the phi29 
packaging motor for specific targeting and treatment of prostate cancer cells. RNA 
nanoparticles were proven to remain chemically and thermodynamically stable after the 
addition of functional groups off each branch. The LNCaP prostate cancer specific 
nanoparticles produces excellent binding profiles, displaying binding at over 90% at 100 
nM RNA concentrations and later proved to provide specific delivery of anti-miRNA 
sequences for the knockdown of miR17 and miR21, two common oncogenes. Significant 
knockdown of miR17 and miR21 and up-regulation of PTEN indicated the positive and 
specific delivery by the pRNA-3WJ RNA nanoparticles in in vitro and in vivo. Through 
these studies, RNA nanoparticles have been developed that have the capability to target 
tumors primary and metastatic tumors as well tumors after hormone deprivation 
treatments. Furthermore, anti-miRNA sequences have been shown to control tumor 
growth and proliferation, while having the possibility to prevent PSMA tumors from 
transitioning to hormonal independent states.  
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Chapter 5: Future Direction and Current State of the Field 
 
CONCLUSIONS AND FUTURE DIRECTION: 
 In this thesis work is described for the advancement of the RNA nanotechnology 
field. In the past RNA nanoparticles have been limited due to their lack of stability to 
nucleases found in the body and their thermodynamic stability. As a result the promises 
of RNAi technologies have been ignored and the once strong interest has disappeared. 
Here in Chapter 2 and Chapter 3 of this dissertation, the instability of RNA has been 
overcome. By using previously developed 2-Fluoro modifications RNAs are now 
resistant to nucleases that are found in vivo. From the data here the pRNA-3WJ has 
proven to be a thermodynamically stable branched motif allowing for the conjugation of 
up to three functional groups. The novel assembly of the pRNA-3WJ of three RNA 
strands assembling in a one-step assembly that is entropically favored results in a ultra-
stable RNA molecule stable to 29.5 pM and 69.8 °C. These findings were then translated 
into developing RNA nanoparticles for the specific targeting and delivery of anti-miRNA 
therapeutics to LNCaP prostate cancer cells. The pRNA-3WJ produced stable RNA 
nanoparticles that resulted in the knock-down of miRNA-21 and -17, ultimately leading 
to the apoptosis of the LNCaP cells, while displaying no toxic effects to PSMA- cells. 
Here the pRNA-3WJ has proven to be a stable, versatile RNA motif that revives the 
previous excitement behind RNAi therapeutics by overcoming previous roadblocks of 
instability. 
 However, in order to fully prove the potential of the pRNA-3WJ and RNA 
nanotechnology for the treatment of prostate cancer, future work is need. While it is 
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proven that the pRNA-3WJ based nanoparticles can target and treat prostate cancer cells 
in vitro and in subcutaneous xenograft tumors, and similar nanoparticles have been tested 
on other cancer models in vivo in mice; the PSMA-3WJ-anti-miRNA-21 and -17 need to 
be tested in a further tested more extensive mouse models to make proper conclusions for 
the applications in humans. It is generally accepted that pRNA-3WJ nanoparticles do not 
display any toxic effects or have long lasting accumulation in healthy organs; 
characterization of prostate cancer targeting and treatment of a solid prostate cancer 
tumor is needed. While a subcutaneous xenograft is a simple animal model to create, 
orthotopical models of prostate cancer would provide a more representative tumor model 
within mice. This would allow for a more hormonal dependent environment for proper 
tumor growth. In testing the RNA nanoparticles should be assayed for targeting and 
honing to the tumor developed in the mice as well as monitoring the tumor growth after 
treatment of the RNA nanoparticles. Futhermore, it is thought that the targeted miRNA-
21 and -17 play roles in metastasis of prostate cancer and the created RNA nanoparticles 
may be able to control this action. If this is to be true extended studies in mice with a 
metastasis model treated with A9g-3WJ-anti-miRNA nanoparticles is to be tested. 
Furthermore, it should be confirmed that the RNA nanoparticles do not have any toxic 
effects or accumulations in healthy organs within the mice. If the future in vivo testing of 
the PSMA-3WJ-anti-miRNA nanoparticles remains as promising as presented here, 
further development into clinical trials should be considered. 
CURRENT STATE OF THE FIELD: 
 Since the development of RNA nanotechnology in 1998 (12), the field has come a 
long way covering several hurdles that once blocked its progress. With the current growth 
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and findings of the most recent research, RNA nanotechnology has a possibility of 
bringing the initial promise of RNAi therapeutics to fruition. Previously RNA 
nanotechnology was not thought of for the treatment of cancers and viral infections due 
to several limitations of RNA, most notably the cost of production, susceptibility to 
RNases found in throughout the body, thermodynamic stability and dissociation of the 
RNA strands. Progress through the field has overcome most of these limitations. 
 As described in this dissertation, RNAs have now been proven to remain stable 
both against nucleases and dissociation. Chemical modifications to the carbon ring of 
RNA has shown to produce nucleic acid structures that are stable against nucleases (189) 
and are stable in vivo as shown in mice (87,123,137,139). Additionally these 
modifications have also been shown to increase the thermodynamic stability of the RNA 
structure (223). The Phi29 pRNA three-way junction motif has been tested and proven to 
remain stable at ultra-low concentrations and does not dissociation when placed into 
mice. Furthermore, several other RNA nanoparticles have been constructed and shown to 
be stable during in vivo testing (264-266). These recent results have shown the RNA 
nanotechnology has overcome two previous hurdles blocking the field from growing. 
 Previously, one of the major limitations of RNA nanotechnology was the cost of 
production and limitations to the size of production. RNA is typically produced through 
in vitro transcription with T7 RNA polymerase (177,267) or through chemical synthesis. 
In vitro transcription of RNAs provides a relatively low cost of production; however, not 
only is the process time consuming, the batch size of production is normally limited to a 
small scale that is far too small to be used for human dosing. Additionally the production 
of RNA through T7 polymerase created some level of error in both the length and 
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sequence created, requiring purification of RNA strands to remove off-target, undesired 
strands. On the opposite spectrum chemical synthesis provides very specific RNA 
products. However, the cost of production of RNA through chemical synthesis was cost 
prohibitive in order to produce RNA on a scale needed for clinical testing. Additionally, 
the chemical synthesis was limited to synthesizing RNA to sizes below 60 base pairs. The 
limitations behind each of the methods thus limited the large scale production of RNAs 
needed for clinical trials. However, recent work and efforts have targeted the production 
of RNA to lower the cost and increase the scale of production. Chemical synthesis of 
RNAs have now increased the length able to be produced and continues to grow. 
Additionally large scale production has now been produced to reach up to gram scale 
synthesis, while lowering the cost of production. Furthermore, techniques have been 
developed for large scale purification of RNAs (268). As technologies advance the 
production of RNA for in vivo testing and moving to translational work will only 
advance, making RNA nanoparticles a viable product as the cost will continue to 
decrease and become more reasonable.  
 While the field of RNA nanotechnology is considered relatively young compared 
to other nanotechnology fields, it has recently proven to be a promising area of research 
for the treatment of cancers and viral infections. RNA nanoparticles are now to the point 
that they have proven to work and function properly and at a non-toxic level in vitro and 
in vivo in animal testing; and are approaching the point in which they will undergo 
clinical testing. Methods in large scale production of RNA is now possible to provide the 
demand of large amounts of RNA that will be needed for delivery into humans. After 
close to two decades of growth, the field of RNA nanotechnology has reached a point in 
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which the hurdles that were once limiting the growth have been overcome and now 
research and testing of the particles can move forward unhindered. 
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APPENDICES 
APPENDIX 1: DERRIVATION OF KINETICS MODELS 
Association Phase: 
 In the reaction:   3 3 3 	3 the rate equation will be as below 
3
3 3 3 3  
In solving this reaction it will be assumed that 3WJc is the ligand strand bound to the SPR 
chip surface and 3WJa and 3WJb strands are the analyte strands flowing over the chip 
surface. In this case, the [3WJa] and [3WJb] are at a much higher concentration than 
[3WJc] and the formation of 3WJ will result in no noticeable change in the concentrations 
of [3WJa] or [3WJb] therefore: 
3 3     
and 
 3 3  
additionally 
 3 3  
To solve the differential rate equation, x will be the [3WJc] that has been converted to 
[3WJ]. Therefore 
3 3  
and 
3 3  
This gives a new differential equation of 
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3 3 3 3  
Or 
3 3 3  
Next, at equilibrium the reaction forward forming 3WJ is at the same rate as the reverse 
reaction forming ssRNAs; the following equations are true  
3 3  
3 3  
3 3 3 3 3 3  
These equilibrium equations can be plugged into the differential equation 
3 3 3  
Or rearranged to 
3 3 3 3  
Where the first term is equal to zero at an equilibrium state, resulting in 
3  
The integration of this differential leads to 
3  
ln 3  
Or 
ln 3  
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Exponential of both sides leads to  
1  
Here x is replaced with Response from the SPR which is direct proportion to [3WJ], 
expressed as R 
1  
Solving for Req: 
At a steady state of the reaction of ssRNA folding to the pRNA-3WJ, the change in 
response is expressed as 
0 3 3  
Where R is the [3WJ] and Rmax is the maximum 3WJ that can be formed and is limited to 
[3WJc]. Therefore, 
3 3  
R is replaced with Req since the reaction is at steady state 
3
3
 
Dissociation Phase: 
The dissociation of the pRNA-3WJ is considered unimolecular and rate of reaction is 
expressed as  
3
3  
Again the [3WJ] is placed in terms of Response from the SPR machine and the rate 
differential equation id then expressed as 
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The simple differential is then solved through integration to 
 
 
ln ln  
Taking an exponential on both sides results in 
 
 
Therefore the SPR curves can be modeled using the following equations for the 
association and dissociation phases, respectively. 
3
3
1  
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